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1 
Overview 
 
This submission from the New Zealand Institute of Gene Ecology (NZIGE) is meant to 
support Food Standards Australia/New Zealand’s preparation of a Draft Assessment on 
application A549. Our comments and wording are direct, but our spirit is constructive.  The 
NZIGE is dedicated to the development for the public good of all responsible 
biotechnologies. We are an assemblage of serious researchers with independent credentials 
in the area of biotechnology and its social impact. The activities of the NZIGE were 
supported in part by a grant for the Biosafety Forecast Service of the Biosafety Capacity 
Building Package under the auspices of the Norwegian Institute of Gene Ecology 
(GENØK). 
 
A549 is an application to amend the Australia New Zealand Food Standards Code to allow 
foods derived from corn line LY038 to be sold in Australia and New Zealand. “Corn line 
LY038 has been genetically modified to have higher than usual levels of the amino acid 
lysine,” particularly in the corn grain.1 LY038 was modified by the gene cordapA, sourced 
from the bacterium Corynebacterium glutamicum, inserted into the corn genome using 
genetic engineering techniques. The gene “encodes the enzyme dihydrodipicolinate 
synthase (DHDPS). This enzyme is involved in lysine biosynthesis. The bacterial DHDPS 
enzyme, unlike the plant DHDPS enzyme, is not sensitive to lysine feedback inhibition, so 
lysine biosynthesis will continue in the presence of high levels of free lysine.”2 
 
Our submission begins with introductory material describing who we are and why we are 
involved. We then provide a summary of the major recommendations gathered from the 
detailed sections of our submission. These sections are organized into three main parts. In 
Part One, we undertake risk forecasting, an exercise at the leading edge of the research 
literature that serves to forewarn of risk where the science is not certain. Novel potential 
hazards of C. glutamicum Dihydordipicolinate Synthase (cDHDPS) protein, its metabolic 
products expressed in maize, and other side-effects of inserting DNA into the maize 
genome were identified to the best of our ability on the very tight timeframe available to us 
for this phase of consultation. Some of these properties, moreover, will be particularly 
influenced by the protein’s environment and thus are even more important for assessments 
of food safety. 
 
In Part Two, we review the scientific documents submitted by the Applicant in support of 
A549. We judged this material by two criteria: 1. Was the science at the best possible 
standard? and 2. Does the science add up to a package that is sufficient to assure the 
citizens of Australia and New Zealand that they may safely consume food derived from 
corn line LY038? In most cases we recommend how, why and when the Applicant should 
supplement their findings with additional data. 
 
In Part Three, we comment upon the Impact Analysis contained in the Initial Assessment 
Report (IAR). We assess the costs and benefits listed and propose further costs and benefits 
                                                 
1FSANZ (2004). Initial Assessment Report: Application A549 Food Derived from High Lysine Corn LY038, 
p. 6. 
2Ibid, p. 9. 
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of the options under consideration. 
 
The Authority (FSANZ) has made plain “the need for standards to be based on risk analysis 
using the best available scientific evidence”3. Above this need is the objective of the 
“protection of public health and safety” and “the provision of adequate information relating 
to food to enable consumers to make informed choices”4, which requires the Authority to 
determine if the best scientific evidence available is good enough. Our contribution has 
therefore been to help the Authority identify areas of scientific uncertainty in the 
application so that these uncertainties can be addressed during the Authority’s development 
of a complete assessment. 
 
We provide compelling new scientific evidence of risk and hazard. We also cannot exclude 
certain hazards from the information in the studies submitted by the Applicant and made 
available to the public by FSANZ. 
 
• The transgenic protein cDHDPS may have a different risk spectrum when a 
component of food. 
• cDHDPs and its catabolic products could create novel risks in processed or 
cooked food. 
• The creation of novel RNA molecules by insertion of DNA into the maize genome 
could create species of RNA that are harmful to humans, possibly through food. 
• The molecular characterization of the DNA inserted into the maize genome, the 
LY038 event, and DNA donated from the transgenic Cre-recombinase line used to 
create the LY038 maize line, is incomplete. The present data does not exclude, 
with a high level of confidence, the possibility that corn line LY038 contains 
additional novel genes, be they derived from the expression of fragments of 
inserted DNA or novel fusion proteins created at the junctions of inserted DNA 
and the maize genome. 
• The molecular characterization of the transgenic protein cDHDPS produced by 
the genetically modified plant is flawed because the Applicant has not 
demonstrated that all novel proteins were included in this analysis. 
• The digestibility study of cDHDPS, required as part of an assessment of 
allergenicity, does not meet FAO/WHO standards for concentration of pepsin or 
standard comparisons to known allergens. Moreover, the digestibility study was 
fundamentally flawed by not using material from the actual genetically modified 
organism that the people of Australia and New Zealand would be eating. 
• An adequate molecular characterization of all novel RNA molecules, that may 
pose a risk to consumers, is missing along with microarray analysis of the 
transcriptome of the LY038 line. There is published evidence that genetic 
components of the LY038 event produce novel RNA molecules. There is also 
evidence in animal studies that some small RNA molecules can be transmitted 
through food, causing lasting, sometimes heritable, effects on consumers and their 
                                                 
3FSANZ (2004). Initial Assessment Report: Application A549 Food Derived from High Lysine Corn LY038, 
p. 9. 
4Ibid, pp. 8-9. 
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children. 
• The data comparing the composition of the transgenic lines to commercial 
reference lines of maize may be skewed by selective choice of commercial lines. 
The commercial reference lines chosen may inflate the 99% tolerance interval to 
more closely match the composition of LY038, thereby reducing the apparent 
number of significant compositional differences between the LY038 line and 
conventional corn. 
• The compositional analysis does not appear to fully support the conclusion of 
equivalence between LY038 and its closest relative. The comparison found 103 
(26% of total comparisons across 5 field studies) statistically significant 
differences between LY038 and the negative segregant. 
• The acute toxicity study was fundamentally flawed by not using material from the 
actual genetically modified organism that the people of Australia and New 
Zealand would be eating. 
• The broiler performance study may have falsely overestimated the positive effects 
of LY038 on chickens due to the choice of commercial reference controls. 
• The broiler performance study indicates some unexplained negative effect on 
growth over the first 21 days when broilers were fed LY038. 
• A549 lacks a subchronic toxicity study of adequate duration to conclude that the 
amino acid levels in LY038 are safe. 
• A549 lacks a long-term toxicity and carcinogenicity study necessary to conclude 
that the amino acid levels in LY038 are safe. 
 
We also provide information and analysis indicating that the Impact Analysis is currently 
incomplete in some respects and mistaken in others.  Addressing these deficiencies would 
significantly shift the balance of the analysis. 
 
We encourage a precautionary approach when assessing LY038. The scientific community 
is not uniformly convinced about the adequacy of existing risk assessments (Pusztai, et al. 
2003), comfortable with the evidence that genetically modified food organisms are 
generally safe (Pryme and Lembcke 2003), nor confident that if approval were revoked, a 
GMO could be removed from the food chain before it caused harm (Heinemann, et al. 
2004). 
 
FSANZ has stated that the primary data5 received from Applicants in support of their 
claims “enables a more rigorous analysis of experimental outcomes than the summary data 
of the type submitted in support of publication of a scientific article in a peer reviewed 
journal.” On the contrary, the data we have seen in A549 is not so different from that 
included in papers we have reviewed for journals. Nevertheless, direct access to the 
primary data is certainly an important requirement. It is important to note that, just as when 
peer-reviewing papers for publication, the reviewer cannot ‘tweak’ the experiment or 
                                                 
5Not ‘raw’ data as indicated in the FSANZ document “FSANZ Response to Article Entitled ‘GE Foods and 
Human Health Safety Assessments’ By Dr Judy Carman, Spokesperson on GE Food, Public Health 
Association of Australia”, unless FSANZ receives machine print-outs and traces as well as photographs and 
tables. 
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explore all the unwritten parameters. This can lead to mistakes in reviewing. And while the 
publication of a paper with a flaw generally has very little influence on the daily lives of 
most citizens, the change in the New Zealand and Australia Food Code has implications for 
tens of millions of people directly and, because it may be connected to changes in global 
agriculture, it could have global ramifications. Therefore, the standard of review must both 
be better and more interrogating than for routine research results submitted for publication. 
 
We have the view that truly good biotechnologies will be vindicated by not just the best 
available science, but science adequate to the task of making a sound decision on safety. 
Our a priori view is this: it is not a given that the science of the day is adequate for the 
task. It is possible for an applicant to do state-of-the-art analyses and not meet a standard of 
risk identification or resolution that may be necessary. 
 
Should the best available science be ambiguous on A549, then New Zealand’s 
precautionary stance (as defined by the Convention on Biodiversity and the Hazardous 
Substances and New Organisms Act 1996 and amendments) must take priority. 
  
 
 
Principal authors of this submission: Assoc. Prof. Jack A. Heinemann (NZIGE, Biosafety 
Forecast Service), Camilo Rodriguez-Beltran (NZIGE, Biosafety Forecast Service), Dr. 
Joanna Goven (NZIGE, Biosafety Forecast Service), Billie Moore (NZIGE, Biosafety 
Forecast Service), Leighton Turner (NZIGE), Dr. Thomas Bøhn (GENØK), Assoc. Prof. 
Juliet A. Gerrard (NZIGE), Marina Cretenet (NZIGE, Biosafety Forecast Service) and Prof. 
Terje Traavik (GENØK, Biosafety Forecast Service) 
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Abstract 
 
In the IAR, FSANZ invited “individuals and organizations to assist FSANZ in preparing 
the Draft Assessment for” this application A549 (FSANZ 2004, p. 3). Significant new 
evidence and analysis that is specifically relevant to the evaluation of LY038 is provided to 
support FSANZ in their preparation of a Draft Assessment. Our submission relates to “the 
scientific aspects of this Application, in particular, information relevant to the safety 
assessment of food from corn line LY038” (FSANZ 2004, p. 7). It also addresses the 
consistency of the IAR with “the objectives of FSANZ as set out in section 10 of the 
FSANZ Act” and provides “details of potential costs and benefits of the proposed change 
to the Code” (FSANZ 2004, p. 3).  
 
In Part One, we describe important structural differences between mDHDPS and cDHDPS 
that produce novel challenges for studies on allergenicity, developments in food safety 
science regarding novel aggregates that could be produced by transgenic cDHDPS, the 
importance of characterizing post-processing and cooking effects on lysine, lysine 
catabolites and cDHDPS itself, novel regulatory RNAs that may have physiological effects 
on human consumers and species of DNA that could have biological effects if taken up by 
human cells through food. 
 
In Part Two, we provide the Authority with a detailed examination of the molecular 
biological data supplied by the Applicant. We find suggestions in the Applicant’s data that 
secondary insertions into the LY038 genome may have been overlooked, and find 
deficiencies in protein identification protocols that could lead to false confidence in the low 
number of novel proteins and post-translational modifications reported in A549. Most 
importantly, new evidence suggests that the nos terminator sequence used in LY038 is a 
recombination hotspot, prone to read-through and may contain a cryptic cis-acting splice 
sequence that could generate novel RNA molecules and proteins at any place it is inserted 
into the genome. The lack of holistic proteomic and microarray analysis is a serious 
deficiency of this application. 
 
In Part Three, we evaluate the cost/benefit analysis conducted by the Authority. One of our 
chief concerns with this analysis is that the costs and benefits included are largely 
concerned with feed while the Authority is considering whether to amend the food Code. 
Only when the place of feed-related impacts in a food assessment is clarified can one 
accurately assess the costs and benefits of Options 1 and 2. We also note that significant 
costs and benefits have been omitted from the analysis, and evidence is lacking to support 
those that have been included. In addition, the premises underlying some of the listed costs 
and benefits require further scrutiny.  
 
Our conclusion is that significant additional information should be provided by the 
Applicant before the Australia New Zealand Food Code is amended. There have been 
important advances in biosafety and risk assessment science that are not uniformly reflected 
in the standard of reporting in A549. The studies submitted in support of A549 no longer 
uniformly meet what we see as the standard of the science.  
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We have raised bona fide issues of safety that have not been addressed by the Authority or the 
Applicant, which also increases the cost of amending the Code. We have not found in the 
economic analysis any evidence of how amending Standard 1.5.2 will directly reduce food 
costs. In fact, we see no evidence that the consumer stands to receive any food benefit form 
amending the Code, while some consumers will certainly bear additional costs from doing so. 
We therefore must reject most of the Authority’s speculation on benefits in opting for Option 
2. 
 
Should the Authority come to recommend that the Code be amended to include event LY038, 
then it is our opinion that a special condition be imposed upon event LY038. In Column 2 of 
the Table to Clause 2 of Standard 1.5.2, LY038 but not any other members of the LY038 line 
currently in existence or that may arise through breeding, hybridization or transformation in 
the future may benefit from a favorable assessment of LY038. In other words, approval of 
LY038 does not extend to other lines of maize that share parentage or the I-DNA with LY038. 
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I. Introduction 
 
I.1 This submission is the opinion of the submitter on Application A549 – high lysine 
corn LY038 ‘MAVERA HVC with Lysine’. 
 
I.2 The submitter is the New Zealand Institute of Gene Ecology (NZIGE) and its 
cooperating partners. Responsibility for the content of this submission rests solely 
with the authors and NZIGE. The NZIGE is a research organisation 
(www.nzige.canterbury.ac.nz). The NZIGE has no commercial interest in the product 
at the focus of this application, no direct or indirect connections with the Applicant, 
and has no connections to parties that seek to compete with the Applicant by 
developing a similar novel food. We received substantial support for the research that 
informs this application through a grant from GENØK for the Biosafety 
Forecast Service, and additional support from the University of Canterbury. Our 
submission is further informed by our own extensive experience in the research areas 
discussed below. If there were to be a public hearing on the application, we would be 
pleased to present our view.  
 
I.3 Our submission relates to “the scientific aspects of this Application, in particular, 
information relevant to the safety assessment of food from corn line LY038” 
(FSANZ 2004, p. 7). It also addresses the consistency of the IAR with “the 
objectives of FSANZ as set out in section 10 of the FSANZ Act” and provides 
“details of potential costs and benefits of the proposed change to the Code” (FSANZ 
2004, p. 3).  
 
I.4 We have done our best to evaluate the scientific documents supplied by the 
Applicant in support of the application. Some areas of uncertainty may have arisen 
from the poor reproduction of some material made available by FSANZ for our use.  
 
R. Summary of major recommendations 
 
R.1 In order to make an assessment of the changes in protein expression that occur within 
the plant due to expression of cDHDPS, the Applicant should undertake a routine 
proteomic analysis (by comparative 2D electrophoresis and mass spectrophotometric 
analysis of relevant spots) of lysates from whole plant cells and demonstrate that the 
only change is expression of the inserted gene. Single dimension protein gels of 
whole plant extracts at various stages of purification should also be supplied, in order 
to authenticate the purification of cDHDPS from plant tissue. Presentation of only 
the purified protein is unacceptable. 
 
R.2 The Authority should require data from long term (lifetime) animal feeding trials to 
capture chronic effects, detect carcinogens and co-carcinogens, and proteins that are 
capable of forming amyloid fibrils. 
 
R.3 The Authority should request an analysis of Maillard reaction products or other 
glycotoxins that could arise from cooking or processing of LY038 corn. 
 
R.4 The Applicant should test the potential of in planta-produced cDHDPS to form 
amyloid fibrils and measure the cytotoxicity of aggregates and intermediate forms 
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compared with native cDHDPS. It would be highly desirable to have the aggregation 
potential of cDHDPS correlated with changes in pH and other varying physical 
parameters of the choloroplast. 
 
R.5 In order to make an assessment of global changes in the transcriptome, and specific 
changes cause by the insertion(s) of I-DNA, the Authority should require microarray 
descriptions capable of detecting novel RNA species in the modified plant, with the 
RNA source being the plant grown under a variety of relevant field conditions. The 
microarray should comprehensively represent the genomes of the cultivar of maize 
modified and unmodified, and any novel RNA species should be tested against the 
human genome for RNAi activity. 
 
R.6 We recommend that I-DNA, especially the Glb1 promoter sequence, be analysed for 
putative mammalian transcription factor binding motifs. 
 
R.7 We recommend that a metabolomic analysis such as NMR combined with 
chemometrics and univariant statistics be supplied to the Authority by the Applicant. 
 
R.8 The Authority should require the Applicant, at a minimum, to supply data on the 
digestibility of the cDHDPS protein using a protocol consistent with the FAO/WHO 
standard (FAO/WHO 2001) and the recommendations of Pusztai et al. (Pusztai, et al. 
2003). 
 
R.9 We recommend that a compositional analysis that includes the four commercial 
varieties used in MSL-18883 be requested by the Authority. 
 
R.10 We recommend that the Authority dismiss study MSL-18883 for purposes of 
assessing safety. 
 
R.11 The Authority should require the Applicant to submit data on cholesterol 
concentrations in serum and lipoprotein, and any changes in liver phospholipids, in 
animal feeding experiments. 
 
R.12 We recommend that the Authority request the Applicant to provide a valid 
subchronic toxicity study of a minimum of 6 months duration. 
 
R.13 We recommend that only after the Applicant demonstrates the safety of LY038 using 
a higher standard of in vitro and animal in vivo safety tests, then human tests should 
be completed before another application is lodged with the FSANZ. 
 
R.14 A plan for effective post-launch monitoring should be provided by the Applicant and 
the plan should be subject to a transparent review through the independent scientific 
community. 
 
R.15 The Authority should clarify its proper jurisdiction with regard to this Application; 
in particular, it should clarify whether and how it is equipped to analyse the impact 
of the availability or non-availability of LY038 animal feed. 
 
R.16 We urge the Authority to disregard the declared intention of the Applicant to 
segregate LY038 from the human food supply, as it cannot bind the Applicant (or 
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any other party) to this action once the Food Code has been amended. We 
recommend that the Authority ensure that this declared intention not be permitted 
to influence the rigour of the application or the analysis of its impacts. 
 
R.17 The Authority should clarify the reasoning behind its identification of Affected 
Parties; in particular, it should clarify why failing to amend the Food Code would 
prevent animal growers accessing LY038 feed. 
 
R.18 The Authority or Applicant should provide evidence for its assertion that the cost 
to consumers of avoiding LY038, and to government of monitoring for the 
presence of LY038 in food, will be low. 
 
R.19 The Authority should not extend any approval of LY038 to any hybrid line derived 
from LY038. As in European regulation, all hybrids, whether between LY038 and an 
unmodified line or another approved modified line, must in this case be treated as a 
new organism requiring a full safety evaluation. 
 
R.20 The Authority should take into account the implications of approving this 
amendment of the Food Code for New Zealand’s obligations under the Cartagena 
Protocol. 
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Part One: Risk forecasting 
 
(1) Potential proteome, transcriptome and genomic changes 
 
1.1 Structure and biochemistry of prokaryotic vs. eukaryotic DHDPS 
 
1.1.1. Whilst there is no doubt that the bacterial and plant enzymes share a common 
biochemical function (albeit with altered regulatory patterns) and perform identical 
chemistry in vitro, there are important differences between the two types of enzyme 
that do not seem to have been appreciated by the Applicant. 
 
1.1.2. The C. glutamicum enzyme (cDHDPS) shows high similarity to the Escherichia 
coli enzyme, the structure of which has been solved (Mirwaldt, et al. 1995). 
Similarly, the maize enzyme shows a high similarity to the only plant enzyme, that 
from Nicotiana sylvestris, for which the structure is known (Blickling, et al. 1997). 
Both prokaryotic DHDPS and eukaryotic DHDPS are tetrameric and have a 
common fold in their tertiary structure. 
 
1.1.3. Natural DHDPS is a highly unusual enzyme, however, in that the bacterial and 
plant enzymes have an entirely different quaternary structure due to a profound 
rearrangement of the dimers forming the tetramer. This difference in molecular 
architecture means that different faces of the protein are presented to the solution. 
 
1.1.4. The key concern of this observation is that the epitopes of mDHDPS and in planta-
produced cDHDPS could be very different and the potential allergenicity of the 
transgene may be different from expected. 
 
1.1.5. New allergens in maize could be especially problematic for some groups of people. 
This highlights one of the social implications of commercial GMOs. There is an 
increasing awareness in the medical community of the allergenicity of wheat 
proteins to a high portion of the Western population, resulting in coeliac disease 
(sprue) and related diseases associated with gluten intolerance. Some studies 
estimate that 1 in 300 people are coeliac, with a much higher number suffering 
some form of gluten intolerance (Kennedy and Feighery 2000). Such individuals 
rely heavily on maize as one of the few commercial grain crops that is safe to eat, 
and may have particular concerns about the potential allergenicity of proteins 
derived from transgenes especially because they might further reduce food options. 
 
1.2 Potential differences in the tendency of maize DHDPS (mDHDPS) and cDHDPS and 
their degradation products to form toxic aggregating species (e.g. amyloid fibril 
precursors). 
 
1.2.1. “Aggregation is a general feature of proteins and can be classified into two types: 
in vivo aggregation such as inclusion body formation and in vitro aggregation such 
as denaturation-induced aggregation. Amyloid fibril formation is an in vivo 
phenomenon, but it also occurs under artificial conditions in vitro” (Ohnishi and 
Takano 2004, p. 517). The aggregation to which we refer is ordered aggregation or 
amyloid fibrils (Fernandez-Escamilla, et al. 2004). 
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1.2.2. Protein misfolding and subsequent aggregation into amyloids are hallmarks of a 
group of diseases termed “amyloidoses”. While the toxic form of the protein is still 
debated, it is most likely an intermediate between the native and fibril form of the 
protein (Bucciantini, et al. 2002). 
 
1.2.2.1 Amyloid fibrils are also found in neurodegenerative diseases such as 
Parkinson’s disease (PD), Huntington’s disease (HD), and the prion diseases 
(transmissible spongiform encephalopathies, TSEs) (Dobson 2001). Other 
non-neurological amyloidoses include hypercholesterolaemia, type II 
diabetes and primary and secondary systemic amyloidoses (Chiti, et al. 2000, 
Dobson 2001, Pepys 2001). “There are also various local forms of 
amyloidosis in which deposits are confined to specific foci or to a particular 
organ or tissue. These may be clinically silent or trivial, or they may be 
associated with serious disease”(Pepys 2001, p. 203). 
1.2.2.2 Probably all proteins can form amyloid fibrils under conditions encountered 
in some intracellular environments, as mild denaturing conditions that in vitro 
conditions mimic, or if primary structure favours re-folding (Chiti, et al. 
2000). The intracellular compartments within lysosomes, the ER and 
proteasomes may be especially conducive to refolding. 
1.2.2.3 Although each of the known amyloidogenic proteins has a distinct function 
and shows no significant similarity in sequence and native structure to any of 
the other proteins of that family, they all adopt a very similar conformation 
when aggregated in amyloid deposits. 
 
1.2.3. Even normally benign proteins can produce cytotoxins as they transit from partially 
to fully unfolded states and eventually form amyloid fibrils (Ellis and Pinheiro 
2002, Fernandez-Escamilla, et al. 2004) although some evidence suggests that 
granular aggregates can also be toxic (Bucciantini, et al. 2002). 
 
1.2.3.1 “The data, therefore, suggest that impairment of cell viability by protein 
aggregates of the type that can subsequently form amyloid fibrils could be a 
general phenomenon and not simply a specific property of the small number 
of polypeptides associated with clinically recognized protein deposition 
diseases. This result is of particular significance in the light of the recent 
conclusion that the ability to form highly ordered amyloid fibrils is itself a 
generic property of proteins” (Bucciantini, et al. 2002, p. 509). 
 
1.2.4. Amyloid fibrils may or may not be harmful to the organism in which they arise, or 
the harm may not be apparent immediately, as in Mad Cow Disease and variant 
Creutzfeldt-Jakob Disease (vCJD). Still, they may be transmitted through food and 
are therefore a food safety issue. 
 
1.2.5. The Applicant should test the potential of in planta-produced cDHDPS to form 
amyloid fibrils and use an in vitro human tissue culture assay to measure the 
cytotoxicity of aggregates and intermediate forms compared with native cDHDPS. 
It would be highly desirable to have the aggregation potential of cDHDPS 
correlated with changes in pH and other varying physical parameters of the 
choloroplast. 
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1.2.6. We would not expect potentially dangerous aggregates to be detected in either the 
broiler feeding study or the acute mouse toxicity study, because exposure to some 
aggregated proteins in the amyloid form can take decades to produce an effect. This 
is a reason that the Authority should insist on long term (lifetime) animal feeding 
trials. 
 
1.3 Creation of novel regulatory RNA molecules that also may be transmissible through 
food. 
 
1.3.1. RNA regulatory molecules are best known for their role in causing gene silencing, 
a topic that has only emerged broadly across the scientific community in the past 
six years (Baulcombe 2004). These molecules usually are in the form of double-
stranded (ds)RNA formed by sense and antisense transcripts or stem-loop 
structures within a single polymer. 
 
1.3.1.1 dsRNA gene-silencing by RNA interference (RNAi) (Denli and Hannon 
2003) or RNAi-like pathways include siRNA and miRNA (22-26 
nucleotides) to siRNA-directed DNA methylation (Baulcombe 2004) and 
DNA deletion (Mochizuki and Gorovsky 2004). Silencing instigated by 
dsRNA occurs in organisms of all biological kingdoms (Altuvia and Wagner 
2000, Faugeron 2000, Tchurikov, et al. 2000, Hannon 2002). 
1.3.1.2 Once introduced into a model plant or animal, the effect of dsRNA is 
systemically spread throughout the organism and persists through the entire 
developmental period. Uniquely in humans, so far as is known from tissue 
culture experiments, siRNA species longer than 50 nucleotides cause a 
complete cessation of all gene expression (and thus effectively kill human 
cells) (Gura 2000). When worms ingest bacteria engineered to produce 
dsRNA, the corresponding gene is silenced in the worm (Timmons, et al. 
2001). The dsRNA species is resistant to digestion in the worm’s gut, 
destruction by enzymes in the bacterium, transmits to gut cells and then to 
deeper tissues and, eventually, to the germ line of the animal. The effects of a 
transient exposure to dsRNA in one generation can persist for at least two 
generations. In addition, siRNA from plants made transgenic for a marker 
gene in worms was capable of initiating gene silencing when injected into 
worms (Boutla, et al. 2002). 
1.3.1.3 While dsRNA has specific gene-targets, it is not always clear in advance 
what they will be (Zhao, et al. 2001, Jackson, et al. 2003, Semizarov, et al. 
2003, Scacheri, et al. 2004, Jackson and Linsley). Thus it is critical to test the 
spectrum of genes that may be affected by even “specific” dsRNA molecules 
in the modified organism and any other organism that may be exposed to 
dsRNA from the modified organism by ingestion, grafting or pollination. 
1.3.1.4 The same dsRNA can have physiologically different effects at different 
concentrations. While very small quantities of dsRNA can induce silencing, 
dsRNA has nonspecific effects at lower concentrations than are required to 
induce silencing in, for example, zebrafish. These defects can be seen in 
embryos injected with as little as 30 picograms of dsRNA (Zhao, et al. 2001). 
This makes it imperative to assess the impact of the modification both on 
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expression of other genes in full knowledge of the amount of dsRNA that is 
being produced, and on all other relevant organisms at the full range of 
plausible concentrations to which they may be exposed. 
1.3.1.5 Importantly, the RNA effects are heritable even in multicellular animals, and 
transmit through food (Cogoni and Macino 2000, Timmons, et al. 2001). 
Small RNA molecules developed in the food may have no effect on the plant 
itself, but could transmit to both somatic and germ cells in animal consumers. 
Therefore, microarray data is required to detect unintended and unanticipated 
effects on gene expression in both the modified maize and on consuming 
organisms. 
 
1.3.2. The potential to inadvertently create novel RNA regulatory molecules, usually in 
the form of dsRNA, is too high by chance to ignore. They can be created by 
insertion of the transgene into a previously transcribed region (and not all 
transcripts emanate from ORFs), by aborted transcripts of the new transgene, read-
through of terminator sequences, through fortuitous sequence similarity with an 
endogenous transcript, and by activation of a pseudogene. (For examples of such 
phenomena, see (Rang, et al. in press) and (Hirotsune, et al. 2003)). 
 
1.3.2.1 “[S]ilencing in response to a DNA transgene could still involve a dsRNA 
trigger: the transgene might integrate itself into the genome in such a way 
that a nearby promoter, or an inverted copy of the transgene itself, leads to 
the production of dsRNA, which could in turn enter directly into the RNAi 
pathway” (Mello and Conte Jr. 2004). 
 
1.3.3. The Applicant has made prior claims that RNA “is generally recognized as safe 
(GRAS)”, and thus “the presence of…secondary RNA transcripts themselves raises 
no safety concern”6. But such claims are incongruous with the literature on small 
RNA molecules and gene silencing effects on duplicated genes initiated by mRNA 
(Meister and Tuschl 2004, Mello and Conte Jr. 2004). Surprisingly, the Applicant 
makes no mention of regulatory RNA in its 2002 assertion that RNA is GRAS, nor 
cites any research on RNAi or RNAi-like mechanisms of regulation. 
 
1.3.3.1 The claim that RNA is GRAS was made in defense of findings that event 40-
3-2 in Roundup Ready Soybean had additional inserts beyond that initially 
reported to regulatory authorities before release. 
1.3.3.2 The presence of an additional 250 base pair fragment of the CP4 EPSPS gene 
went undetected in Roundup Ready soybean until 2001 (Windels, et al. 
2001). 
1.3.3.3 In 2002, the Applicant argued that the only relevance of novel RNAs arising 
from read-through of the nos terminator of the full length insert into the 
newly discovered insert would be a novel protein and they could neither 
detect a novel protein using specific molecular tools nor detect the effect of a 
novel protein from their feeding studies.7 However, in an upcoming paper, 
Rang et al. report evidence “that these RNA variants [arising from read-
                                                 
6p. 5 of MSL-17632, dated February 2002 (http://www.food.gov.uk/multimedia/pdfs/RRSsafetysummary.pdf) 
7MSL-17632, dated February 2002 (http://www.food.gov.uk/multimedia/pdfs/RRSsafetysummary.pdf) 
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through of the nos terminator in Roundup Ready Soybean] might code for (as 
yet undescribed) CP4 EPSPS fusion proteins” (Rang, et al. in press). 
1.3.3.4 Even more significant, Rang et al. found that “the read-through transcript was 
processed in four different RNA-variants” (Rang, et al. in press). The variants 
might arise from splicing pathways or other pathways. Post-transcriptional 
processing could signal entry into pathways that produce regulatory RNAs. 
 
1.3.4. A significant concern raised by the authors about these variants, if they arise 
through a splicing mechanism, was that the nos sequence itself harbors a splice site. 
“The cis regulatory regions that initiate and mediate splicing are located within the 
removed region of spliced transcripts. If this is also true for the mechanisms 
mediating posttranscriptional processing of the described variants, it seems 
reasonable to assume that the transcribed nos terminator region might be 
responsible for processing the RNA. Since the nos terminator was and still is 
commonly used as regulatory region in the production of genetically modified 
crops, read-through products and RNA variants could also be expressed in these 
plants” (Rang, et al. in press). Since nos is also used in LY038, these new research 
findings require that it be evaluated for variant RNA species arising from the I-
DNA. 
 
1.3.5. Regardless of whether the variant RNAs arise from a cryptic splice site within nos 
or through other processing pathways, all novel RNA species in LY038 must be 
reported for a proper safety assessment. 
 
1.3.6. Microarray descriptions should be capable of detecting novel RNA species in the 
modified plant, with the RNA source being the plant grown under a variety of 
relevant field conditions. The microarray should comprehensively represent the 
genomes of the cultivar of maize modified and unmodified. Since LY038 may be 
found in food, variant RNAs should be screened for effects on human tissue culture 
cells using a microarray for the human genome. The Applicant should then 
undertake both animal and human trials, but only if no effects are detected using 
tissue culture cells. 
 
1.4 Creation of novel DNA sequences that may be harmful if taken into the human 
genome through food. 
 
1.4.1. If DNA molecules and proteins from GMOs persist in, and are taken up from the 
mammalian gastrointestinal tract (GIT), then this could, theoretically lead to 
development of chronic disease conditions. The fate and consequences of DNA 
persistence and uptake is, however, not extensively studied. 
 
1.4.2. It has generally been claimed that DNA and proteins are totally degraded in the 
mammalian GIT. This has been based on assumptions that had never been 
systematically examined (Palka-Santini, et al. 2003). A restricted number of recent 
publications have demonstrated that foreign DNA (and also proteins) may escape 
degradation at concentrations that allow persistence in the GIT and that such 
macromolecules may be taken up by the intestines, to circulate in the blood, and 
become seeded in internal organs (Schubbert, et al. 1994, Schubbert, et al. 1997, 
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Einspanier, et al. 2001, Hohlweg and Doerfler 2001, Klotz, et al. 2002). This has 
recently been demonstrated also in human volunteers (Forsman, et al. 2003). 
 
1.4.3. Briefly summarized, the present conception of DNA persistence and uptake 
includes long fragments of ingested DNA. DNA may be detected in the faeces, 
intestinal wall, peripheral white blood cells, liver, spleen and kidney, and can cross 
placental boundaries to enter tissues of the fetus (Schubbert, et al. 1998), and the 
foreign DNA may be found integrated into the recipient genome. The state of GIT 
filling, and the feed composition may influence DNA persistence and uptake. 
Complexing of DNA with proteins or other macromolecules may protect against 
degradation. 
 
1.4.4. Extrapolating from a number of experiments in mammalian cell cultures and in 
experimental animals, it is conceivable that in some instances insertion of foreign 
DNA may lead to alterations in the methylation and transcriptional patterns of the 
recipient genome, resulting in unpredictable patterns of gene expression and 
concentrations of gene products. Furthermore, even small inserts may result in a 
so-called ‘destabilization’ process, the end-point of which may be malignant cancer 
cells. 
 
1.4.5. We therefore recommend that the Authority require a complete microarray 
description of the LY038 transcriptome compared to the unmodified control.  
 
1.4.6. We also recommend that an analysis of the Glb1 promoter sequence for putative 
mammalian transcription factor binding motifs be supplied by the Applicant. We 
are concerned that upon in vivo uptake of DNA fragments by mammalian cells, and 
insertion into the recipient cell genome, the promoter may overexpress the 
cDHDPS gene, and/or deregulate the expression of endogenous genes. To what 
extent this hypothetical hazard may represent a real risk, and to which cell types the 
risk(s) is related, may be indicated by the repertoire of putative binding motifs in 
the promoter. 
 
(2) Effects of lysine over-production 
 
2.1 Maillard reaction and glycotoxins 
 
2.1.1. Free lysine is a highly reactive amino acid which can undergo a variety of chemical 
reactions during food processing, notably the Maillard reaction (Meade, et al. in 
press). The Maillard reaction leads to a plethora of products upon food processing, 
including a wide variety of colour, flavour and aroma compounds, potentially 
beneficial compounds such as anti-oxidants, and toxic molecules (Fayle and 
Gerrard 2002). 
 
2.1.2. Cooking and processing conditions can lead to the accumulation of toxic 
compounds from free amino acids. An example of such was demonstrated by two 
groups using asparagine, glutamine and methionine coupled with common 
reducing sugars to produce acrylamide from N-glycosides by the Maillard reaction 
(Mottram, et al. 2002, Stadler, et al. 2002). The ratio of safe to harmful Maillard 
reaction products is dependent on precise reaction conditions, including the 
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temperature, pH and concentration of starting materials. Thus changes to the 
concentration of lysine in the raw materials used to make food and feed may alter 
the toxicological properties of the resulting processed food. 
 
2.1.3. An increasing body of work associates Maillard reaction products with 
inflammatory diseases of the gut. “An unrecognized risk factor for diabetic 
complications is the heat-generated group of advanced glycation end products 
(AGEs) which form in common foods during the spontaneous reactions between 
reducing sugars and proteins or lipids” (Vlassara, et al. 2002, p. 15596). 
 
2.1.4. Thus an increase in lysine concentration may also lead to an increase in Maillard 
reaction products that are associated with inflammation, particularly within the 
growing community of diabetics (Vlassara, et al. 2002). 
 
2.1.5. The Authority should request an analysis of Maillard reaction products or other 
glycotoxins that could arise from cooking or processing of LY038 corn. It is also 
essential that the Applicant supplement application A549 with a complete set of 
long-term, chronic, sub-chronic and acute toxicity feeding studies and allergenicity 
studies using cooked products derived from LY038. 
 
2.2 Lysine and metabolism. 
 
2.2.1. Recent evidence indicates that different proportions of lysine can have specific 
effects on metabolism. 
 
2.2.1.1 In a feeding study of young chickens, the authors observed a significant 
relationship between lysine, arginine and methionine. “These results suggest 
that more concern is prudent when considering the amino acid balance among 
[arginine, methionine and lysine] in the diet of young broiler chicks for 
maximum growth (and muscle creatine)” (Chamruspollert, et al. 2002, p. 
660). 
2.2.1.2 In chickens, the effect is dramatic enough to result in a growth rate defect and 
a reduction in breast muscle creatine unless the diet is supplemented with 
arginine. While it has been known since the 1950s that elevated dietary levels 
of lysine affect arginine requirements in chickens, the connection to 
methionine has only recently become apparent. 
2.2.1.3 In a study on hypercholesterolemia8 in rabbits, it was found that higher 
concentrations of lysine and methionine, alone but particularly in 
combination, had a hypercholesterolemic effect (Giroux, et al. 1999). The 
effect was also correlated with changes in liver phospholipids. Higher 
supplements of arginine would sometimes mitigate the effect. 
2.2.1.4 In the rabbit study, it was possible to create conditions where the animals’ 
weights were not significantly changed under a dietary regime enriched for 
lysine and methionine but the symptoms of hypercholesterolemia were 
significantly different between this and a control group (Giroux, et al. 1999). 
Thus, feeding studies using high lysine corn must include such tests even on 
                                                 
8Note that this disease has also been associated with amyloidoses. 
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animals with no apparent differences in growth. 
 
2.2.2. More research on the effects of dietary lysine in humans is required to evaluate 
potential effects of LY038 in the human food chain. 
 
2.2.3. Animals feeding on plants have adapted to particular levels of total and free lysine 
and any derivative metabolites. In the case of humans, potentially toxic Maillard 
reaction products arising from cooking and processing can arise from a variety of 
amino acids, such as asparagine (Mottram, et al. 2002, Stadler, et al. 2002). Lysine 
is extremely reactive and can produce many toxic products (Fayle and Gerrard 
2002). A change in the lysine concentration may generate new classes of toxins, or 
new concentrations of toxins that are presently extremely rare in our diets. 
 
2.2.4. mDHDPS is feedback-inhibited by lysine, as are all known plant DHDPS enzymes 
(Azevedo and Lea 2001). Why this is the case is not explained by the Applicant, 
but there is evidence that higher levels of lysine alter the metabolism of the plants 
and could be harmful (Azevedo and Lea 2001). Lysine is a feedback inhibitor of 
aspartate kinase (AK), the first step in the common pathway leading to production 
of lysine off one branch, and isoleucine, threonine and methionine off the other 
(Azevedo and Lea 2001). While there is evidence of multiple isozymes of AK, the 
lysine-responsive isozyme is the major activity in maize (Azevedo 2002). Thus, 
plant biochemistry is responsive to lysine concentration. De-regulating DHDPS 
could cause fluxes in the amount of β-aspartyl phosphate available for the second 
branch and vary the concentration of these essential amino acids, proteins or other 
metabolites, or select for compensatory mutations. 
 
2.2.5. Interestingly, the natural limitation to lysine accumulation in maize endosperm is 
lysine catabolism rather than limited production. The LOR-SDH lysine catabolic 
pathway first yields saccharopine by action of lysine 2-oxoglutarate reductase 
(LOR) and then aminoadipic semialdehyde and glutamate via saccharopine 
dehydrogenase (SDH). Maize mutants, and mutants of Phaseolus vulgaris that 
accumulate lysine in seed, also have low LOR-SDH activity (Azevedo 2002). 
 
2.2.6. “The amount of lysine that has been shown to be translocated to the developing 
endosperm for storage protein synthesis is 2 to 3-fold higher than what would be 
needed. Thus, accumulation of lysine in the soluble form would be expected, 
however, that is not the case, since the average concentration of lysine during 
endosperm development is kept low, probably to avoid inhibition of [aspartyl 
kinase] activity and consequently methionine biosynthesis [emphasis added]. These 
results suggested that soluble lysine concentration is mainly controlled by the rate 
of lysine catabolism instead of by the feedback inhibition of its synthesis” 
(Azevedo and Lea 2001, p. 267). 
 
2.2.7. For whatever reason, cDHDPS has achieved a higher concentration of lysine in 
seed in line LY038 (MSL-19172), but this is not unprecedented and has been 
observed among other high lysine mutants of maize (Azevedo 2002).  
 
2.2.8. The observation of lysine accumulation in seed is not consistent with a fully 
functional breakdown pathway. Since LY038 accumulates saccharopine but seems 
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to have normal levels of glutamate (MSL-19172), it may be that SDH catalysis of 
saccharopine hydrolysis is the rate-limiting step in the pathway or that SDH 
function has changed in LY038. This may be a compensatory change in LY038. 
Thus, the phenotype of any resulting hybrid cannot be predicted from the behaviour 
of LY038. 
 
2.2.9. Normally this kind of effect could be considered environmental and not a food 
safety issue. However, this case is special. LY038 may be by luck or adaptation 
particularly resistant to the effects of high lysine. Hybrids that could form in nature 
may not be. The physiological sequelae of this metabolic stress could result in 
changes to the nutrient profile of hybrids that have implications for raw and/or 
cooked and processed products from these sources. 
 
2.2.10. If the Authority were to recommend amending the Code to allow LY038, then it is 
also extremely important for the Authority to impose a condition in Column 2 of 
the Table to clause 2 of Standard 1.5.2 that limits this approval to LY038 without 
extension to hybrid lines derived from LY038. As in European regulation, all 
hybrids, whether between LY038 and an unmodified line or another approved 
modified line, must in this case be treated as a new organism requiring a full safety 
evaluation. 
 
(3) Limitations in knowledge will require post-launch monitoring. 
 
3.1 In this Part of our submission, we have highlighted several serious limitations in 
knowledge about the effects of the LY038 event on food. These limitations will not 
be overcome quickly through more molecular descriptions of the insertion, the 
composition of LY038, or bioinformatics. We will therefore argue for additional 
testing and, if applicable, post-launch monitoring. 
 
3.2 Allergenicity is arguably the most complex and difficult assessment to make 
(Pusztai, et al. 2003). That is why we believe that if LY038 passes more extensive 
animal tests, then human trials are essential as part of an application package to 
FSANZ. To be valid, they must be conducted in controlled settings, not on 
consumers. 
 
3.3 The Applicant should conduct allergenicity studies using a wide range of mildly 
and highly processed and unprocessed foods made from the GMO itself.  
 
3.4 Allergenicity studies must not be limited to dietary exposure for foods that are 
commonly sold as powders or which may become airborne during routine processing 
by the consumer. The study should include an assessment of inhalation challenge as 
well as dietary challenge. 
 
3.5 Until now, a de facto passive surveillance of novel foods has substituted for an active 
monitoring of genetically engineered foods. For example, it is common to hear the 
claim that “Americans have been eating GM for years and they seem alright.” 
However, passive surveillance of consumers falls short of what we would 
recommend for New Zealand, because passive surveillance: 
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3.5.1. detects only “serious acute adverse effects” and is not appropriate for the kinds of 
effects most likely to arise from novel foods (Schilter and Constable 2002); 
 
3.5.2. lacks an intrinsic control population from which baseline data of chronic conditions 
can be extrapolated; 
 
3.5.3. could incur delays if chronic conditions were misdiagnosed; 
 
3.5.4. is not designed as a failsafe for unanticipated errors, such as, for example, the 
adventitious contamination of novel foods with novel feeds approved only for 
animals. 
 
3.6 We recommend that a risk management plan should be submitted by the Applicant as 
part of A549. That plan should include a description of how the Applicant will 
conduct post-launch monitoring (Schilter and Constable 2002). Failure to do so 
would, in our minds, undermine the Authority’s objective of ensuring that consumers 
receive “adequate information relating to food” so that they may make informed 
choices in the long-term. 
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Part Two: Data assessment 
 
(4) Molecular characterization of Cre-recombinase line. 
 
4.1 We argue that assessing the proposed amendment to Standard 1.5.2 requires a 
separate and formal evaluation of the Cre-recombinase progenitor line that includes 
LY038, as well as the provision of the proper molecular data for this progenitor line 
in an evaluation of LY038. 
 
4.2 LY038 is a hybrid9 line of corn derived from a cross between pre-LY038, the 
cordapA-containing plants, and an undescribed transgenic corn line only referred to 
as the Cre-recombinase donor. That donor is a transgenic maize plant modified by 
the insertion of at least the cre recombinase and nptII transgenes (and possibly other 
undisclosed insertions). 
 
4.3 We will make the case that molecular characterization of LY038 with respect to the 
nature of the modifications potentially introduced from the Cre-recombinase line is 
incomplete in certain important aspects. These should be made complete before a 
decision is reached on whether the Code should be amended. 
 
4.3.1. According to Standard 1.5.2 – Food Produced using Gene Technology, “A food 
produced using gene technology, other than a substance regulated as a food 
additive or processing aid, must not be sold or used as an ingredient or component 
of any food unless it is listed in Column 1 of the Table to this clause and complies 
with the conditions, if any, specified in Column 2.” To our knowledge, the Cre-
recombinase donor is not listed in the Table to Clause 2. Therefore, the Authority 
must require a complete analysis of the Cre-recombinase line or be satisfied that 
the analyses submitted in support of LY038 make such an analysis redundant. 
 
4.3.2. We are presently not convinced that the analyses currently submitted are sufficient 
to constitute a retrospective analysis of the Cre-recombinase line. 
 
4.3.3. Up to twenty chromosomes (the 2N number for maize) may have been changed in 
the creation of the Cre-recombinase line, due to unanticipated and uncontrolled 
insertions of partial fragments of plasmid PV-ZM003. Ten of these chromosomes 
would have been present in the F1 hybrid between pre-LY038 and the Cre-
recombinase donor. Assuming that the full length cre and nptII genes from PV-
ZM003 were linked on a single chromosome, then by the F3 generation (from 
which LY038 derives), up to 11 chromosomes would be from pre-LY038 and up to 
9 from the Cre-recombinase line. Of course extensive crossing over during meiosis 
makes even this a simplistic analysis. It is possible for DNA to have crossed over 
between all the Cre-recombinase line and pre-LY038 chromosomes. 
 
4.3.4. Probes 14 (18), 15, 16 (20), 17, 19 and 21-23 (Figures 17-18 of Monsanto Australia 
Limited 2004) were used to generate evidence that LY038 was devoid of DNA 
                                                 
9Figure 5 of Monsanto Australia Limited (2004). Application to Food Standards Australia New Zealand for 
the inclusion of Lysine maize LY038 in Standard 1.5.2 – Food Derived from Gene Technology. 
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sequences that might derive from PV-ZM003. We note the following problems 
with this analysis that should be clarified by the Applicant. 
 
4.3.4.1 The size of the probes ranges from 0.3 to 1.9kb, with most being 1.2 to 1.9 
kb. The Applicant should report the minimum size of target DNA that all 
probes will detect at a minimum stringency of 0.5 copies per genome (see 
Figure 1). Partial fragments of I-DNA or genomic DNA interspersed into I-
DNA have been detected in fragments as small as 15 bp (Svitashev, et al. 
2002). 
4.3.4.2 Even inserts of this small size can be biologically relevant. 15 nucleotides is 
5 new codons, or could create a new transcription factor binding site. Any 
one of the new codons could be a stop codon. Multiples of nucleotides other 
than 3 will put shift the reading frame. Toxic proteins can be produced by 
truncated mRNAs (Wilusz, et al. 2001), themselves often the product of 
insertions10. 
4.3.4.3 The Applicant need meet the dual standard of demonstrating comprehensive 
coverage in their search for PV-ZM003 DNA (which the list of probes does) 
and demonstrating appropriate sensitivity to small inserts (which the data 
does not). 
4.3.4.4 PCR data does not substitute for Southern data because small fragments 
cannot be expected to insert in the correct order or proximity for easy 
amplification. 
4.3.4.5 Importantly, there are a number of light (‘ghost’) bands clearly visible in 
lanes marked LY038(-) in Figure 19 (see Figure 2). This blot is a 
simultaneous hybridization with all probes 14-17, spanning rACT1, cre, 
Zm.hsp70 intron and NOS3’. Since LY038(-) is a negative segregant of 
functional cre and nptII genes, these ghosts could be indicating the presence 
of partial plasmid sequences distributed throughout the genome of the LY038 
line. At a minimum, the Applicant should have included the parental controls 
for comparison. Preferably, the Applicant would have cloned and sequenced 
the ghost bands to determine if they had uncharacterized insertions. 
4.3.4.6 We are confused by the Applicant’s conclusion (Monsanto Australia Limited 
2004, p. 20) that “Hybridisation of Lysine maize LY038 DNA digested with 
Spe I (Lanes 3 and 9) produced an expected unique band of approximately 
3.8 kb in addition to those produced by the LY038(-) control DNA (Lanes 1 
and 5)”. Our confusion stems from the apparent band in this 3.8-4.1 region in 
LY038(-) lanes. The co-migrating band in LY038(-) should be sequenced 
before the Applicant can conclude that ‘[t]his band resulted from the 
hybridisation of the rAct1 intron portion of the probe with the rAct1 intron 
associated with the cordapA cassette”, because it could be that and a second, 
uncharacterized, insertion in the homologous chromosome. 
4.3.4.7 Contrary to the Applicant’s conclusion (Monsanto Australia Limited 2004, p. 
20) that “Hybridisation of Xho I and Xba I-digested Lysine maize LY038 
DNA (Lanes 4 and 10) produced a single unique band of 3.5 kb in addition to 
                                                 
10This is one reason that we argue, below, that a complete description of the transcriptome should be provided 
by the Applicant. 
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the background observed in LY038(-) (Lanes 2 and 6)”, we count 2 bands 
unique to lane 10 (LY038). The larger band, somewhere between 15 and 20 
kb, may be a marker of a chromosome absent from LY038(-) and of Cre-
recombinase line origin. 
4.3.4.8 We would like confirmation that a ghost band visible in Lane 4 (DNA from 
LY038) at approximately 3.1 kb is an artefact to support the Applicant’s 
assertion (Monsanto Australia Limited 2004, p. 21) that “Hybridisation of 
Lysine maize LY038 DNA digested with…the combination of Xho I and Xba 
I (Figure 21, Lanes 4 and 10) showed no detectable band.” We reproduce 
Figure 21 (see Figure 3) to highlight the band in question. The observation 
was not reproducible because the band should also be visible in Lane 10, but 
is not. However, no positive control for hybridization is included in Lane 10, 
making it difficult to dismiss the importance of the band in Lane 4. 
 
4.3.5. The sensitivity of analysis of genomes for insertions of partial transgenes must be 
at least to the standard of published studies that have been able to demonstrate their 
much higher effectiveness at detecting unexpected inserts (Svitashev, et al. 2002, 
Makarevitch, et al. 2003). A combination of FISH, fiber-FISH and Southern 
analysis was used in these studies, whereas the Applicant has only used Southern 
and PCR. These other studies found that even to their much higher standard, they 
failed to detect all insertions initially. They found that “[t]ransgenic oat line 
3830…was previously characterized with FISH, fiber-FISH, and Southern analyses 
and shown to have a single major transgene locus estimated to be ca. 15 kb in 
length. However, when T1 progeny of line 3830 were analyzed by Southern blot 
hybridizations with longer exposure times and more genomic DNA per lane 
compared to these previous analyses, two additional minor transgene loci were 
detected” (Makarevitch, et al. 2003). Their work emphasizes how vulnerable 
analyses are to arbitrary exposure times, probe sizes and wash stringency. 
 
4.3.6. In addition to detecting multiple insertions, these authors sequenced around 
insertion sites and found evidence of transformation-induced genomic 
rearrangements and deletions that again would not be detected by Southern blotting 
using transgene-specific probes. 
 
4.3.7. In their commentary on detecting the many small and/or complex products of 
multiple insertion sites, Kohli et al. (2003) said: “Mehlo et al. (2000) studied seven 
transgenic maize lines with multicopy transgene loci and found that every line 
showed some form of transgene rearrangement in at least one copy. Importantly, 
some of these rearrangements could be detected by sequencing and/or PCR, but 
were too subtle to be picked up by Southern blot analysis, the predominant 
technique used to characterize transgene loci. The authors speculated that 
undetected ‘minor’ rearrangements might be extremely common…However, 
sequencing and PCR analyses by themselves would provide an incomplete picture 
of transgene organization because, depending on the location of the sequencing and 
PCR primers, some major rearrangements might not be detected. Therefore, PCR, 
sequencing and hybridization provide complementary information regarding locus 
structure [emphasis added]” (Kohli, et al. 2003). 
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4.3.8. Additional evidence is also required to verify the Applicant’s claim that “[t]he 
excised nptII gene cassette (circular extragenomic DNA), which did not contain an 
origin of replication, was subsequently lost, most likely through cell division” 
(Monsanto Australia Limited 2004, p. 7). It is not always true that the DNA 
between loxP sites is lost. In a similar strategy to A549, transgenes in wheat were 
removed by crosses with a Cre-recombinase donor (Srivastava and Ow 2003). The 
excised and retained DNA was only detected using PCR, not Southern blotting. 
While these transgenes did not have recognized replication sequences, there is the 
possibility that excised circles replicated (Srivastava and Ow 2003). Depending on 
the efficiency of replication, nptII DNA might persist at less than an average of 1 
copy per genome across the cells of the transgenic plant. The authors only pressed 
their Southern analysis to approximately 0.5 copies per genome rather than, say, 
0.01 copies per genome (or one gene per 100 cells). 
 
4.3.9. Moreover, excision does not necessarily eliminate all effects of the original 
insertion. Reliable combinations of cis-acting sites and excision enzymes can still 
produce excision products that differ from both normal and expectation. Exceptions 
are often such because it is harder to detect events that have been processed 
differently. In one such case, the excision of adenovirus ad12 from hamster tissue 
culture cells, very minor variations of the excision event had spectacularly different 
biological consequences (Pfeffer, et al. 1999). In that case, the oncogenic 
phenotype conferred by the insertion of the virus was retained after excision of the 
virus. Even the subclones that carried “only minute fragments from the right 
terminus of Ad12 DNA, retain[ed] the oncogenic phenotype. Each subclone of the 
hamster tumor cell lines seems to exhibit a different pattern of persisting tiny Ad12 
DNA segments” (Pfeffer, et al. 1999, p. 114). Extreme care must be exercised by 
the Authority in evaluating the DNA sequence surrounding all insertion sites 
including those processed by the cre recombinase. 
 
4.3.10. Although we find evidence of LY038 I-DNA locus amplification by PCR, e.g. 
Figure 22, we cannot find an instance in this application where LY038 DNA has 
been interrogated using PCR and primers for nptII or cre, despite repeated 
statements in the application that loss of nptII and cre was confirmed using both 
Southern and PCR techniques11. We believe that it is essential that the Applicant 
make the PCR data for the cre-recombinase-specific markers clear. 
 
(5) Molecular characterization of LY038. 
 
5.1 We will make the case that molecular characterization of LY038 with respect to the 
nature of the I-DNA in the “cordapA-containing plants” and in planta-produced 
cDHDPS is incomplete in certain important aspects. These should be made complete 
before the decision is made whether to amend the Code. 
 
5.2 Probes 1-13 (Figures 2-3. Monsanto Australia Limited 2004) were used to generate 
                                                 
11“Through extensive PCR screening of subsequent maize breeding progeny, the cre gene was segregated 
away from the cordapA gene such that F3 progeny containing only the cordapA gene cassette in the inserted 
DNA (I-DNA) and lacking both the nptII and the cre gene cassettes were identified and designated as Lysine 
maize LY038” (p. 7). 
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evidence that the LY038 genome has only one complete copy of I-DNA derived 
from PV-ZMPQ76. This analysis should be supplemented by the Applicant in the 
following ways.  
 
5.2.1. The size of the probes ranges from 1.3 to 1.6 kb. The Applicant should report the 
minimum size of target DNA that these probes will detect at the stringency of 0.5 
copies per genome (see Figure 1). Partial fragments of I-DNA or genomic DNA 
interspersed into I-DNA have been detected to fragments as small as 15 bp 
(Svitashev, et al. 2002). 
 
5.2.2. As indicated above, PCR data does not substitute for Southern data because small 
fragments cannot be expected to insert in the correct order or proximity for easy 
amplification. 
 
5.2.3. Importantly, there are a number of ghost bands clearly visible in lanes loaded with 
LY038(-) DNA using probe 5, spanning the Glb promoter (Figure 9, Monsanto 
Australia Limited 2004). Since LY038(-) is a negative segregant, presumably 
missing the cordapA gene, these ghosts could be indicating the presence of partial 
plasmid sequences distributed throughout the genome of the LY038 line. At a 
minimum, the Applicant should have included the parental controls for 
comparison. Preferably, the Applicant would have cloned and sequenced the ghost 
bands to determine if they had uncharacterized insertions. 
 
5.2.4. We are confused by the Applicant’s conclusion (Monsanto Australia Limited 2004, 
p. 18) that hybridisation of LY038 DNA using probe 5 produces a unique band in 
addition to the background observed in LY038 (-) (Figure 9, Monsanto Australia 
Limited 2004). This statement implies that all but one band should be in common 
between the genomes of LY038(-) and LY038, but there is clearly a band of 1.5 kb 
that appears in the LY038(-) control DNA and that is not observed in LY038 
genomic DNA. In MSL-19109 the Applicant concludes that “this hybridization 
could be a result of variances in the genetic background” (p. 22 of 69). At a 
minimum, the Applicant should have included the parental controls for 
comparison, and sequenced the DNA of this band to confirm its identity. 
 
5.2.5. The Applicant should meet the dual standard of demonstrating comprehensive 
coverage in their search for PV-ZMPQ76 DNA (which the list of probes does) and 
demonstrating appropriate sensitivity to small inserts (which the data does not). 
Further characterizations of the LY038 genome are required to the standard we 
discussed in section 4, above. 
 
5.2.6. Finally, the Authority should be aware that processing of loxP sites does not 
entirely reverse the effects of the original insertion nor leave the site with the same 
risk spectrum as before the insertion of loxP sequences. Processing leaves an intact 
loxP sequence in the chromosome. This sequence may make the chromosome 
vulnerable to double strand breaks should, by chance, LY038 produce hybrids with 
a cre containing line [or the cre recombinase gene or activity ever again transfer to 
LY038 (e.g. by horizontal gene transfer)]. This is one reason that we argue, should 
the Authority recommend Option 2, a condition be placed in Column 2 of the Table 
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to Clause 2 restricting approval to LY038 and not to any derivative hybrids. 
 
5.3 MSL-18365 and MSL-18585 attempt to demonstrate equivalence between maize 
DHDPS (mDHDPS), E. coli-produced cDHDPS and in planta-produced cDHDPS. 
 
5.3.1. In MSL-18365 the authors conclude that “[t]he introduction of cDHDPS protein is 
functionally similar to the maize DHDPS enzyme” (p. 11 of 49). Beyond citing a 
1991 study by Frisch et al.12 which discusses mDHDPS, neither this study nor 
MSL-18585 can draw any conclusions about comparisons between mDHDPS and 
any other DHDPS because mDHDPS was never included in the analyses presented. 
Before such statements are accepted by the Authority, the Applicant should submit 
supporting data. 
 
5.3.2. The phrase “functionally similar” is vague. If functional similarity is restricted to 
structural characteristics, then, as we noted in Part One, the eukaryotic and 
prokaryotic DHDPS have different quaternary structures, and this can have 
important implications for safety assessment. We also speculate that the potential 
to form amyloids may be greater for in planta cDHDPS than either E. coli- or C. 
glutamicum-produced cDHDPS because of the expected pH fluctuations in the 
chloroplast. 
 
5.3.3. If functional similarity is restricted to biochemical parameters, such as specific 
activity, Km, or Vmax, then these should be reported for all in planta-produced 
DHDPS proteins. Only specific activities of E. coli- and in planta-produced 
cDHDPS were reported and these, unfortunately, do not establish similarity. 
 
5.3.3.1 In MSL-18585 “[t]he specific activity for the plant-produced and E. coli-
produced cDHDPS protein was estimated to be 68±3 and 84±5 U/mg total 
protein, respectively.” Importantly, the authors concluded in MSL-18365 that 
the specific activity of the enzyme from MSL-18365 was 107±6 U/mg of 
protein, or approximately 23 to 40 U/mg different from the E. coli- and in 
planta-produced cDHDPS, respectively. In published studies, differences in 
specific activity of comparable magnitudes to those in MSL-18365 and 
18585 have been considered significant (e.g. Bessler, et al. 2003). 
5.3.3.2 Simple statistical analyses will demonstrate that, based on a replication power 
of four per assay, the reported specific activities are significantly different13. 
5.3.3.3 Measures of specific activity can suffer from a high variance. With this in 
mind, we suggest that the specific activity data is inappropriate for drawing 
conclusions of identity or functional similarity, other than to say that the 
isolated proteins perform the same conversion of substrate into product in this 
in vitro assay. Either the specific activity measures are significantly different 
and refute the suggestion of functional similarity, except by the most liberal 
of definitions of similarity, or they are unreliably variable and better 
measures, such as Km and Vmax, should be provided. 
 
                                                 
12Note that the bibliography incorrectly lists the first author as Frish, D.A. 
13Student T test p=0.003. 
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5.3.4. Functional similarity could instead be interpreted to mean that the reaction 
mediated by cDHDPS is functionally similar to that mediated by mDHDPS. 
However, cDHDPS is relatively insensitive to lysine feedback inhibition, the 
central attribute of this enzyme for purposes of maize transformation. In our view, 
it is a matter of judgment how to prioritize biochemical functions as more or less 
significant. Contrary to the Applicant, we would consider the difference in lysine 
feedback inhibition and its metabolic consequences as significant and not similar to 
the properties of maize DHDPS. 
 
5.3.5. The reaction an enzyme performs is influence by the environment. Observing a 
common reaction product between two enzymes in the same environment is not a 
positive identification of the range of products the enzyme will make in different 
environments. “[T]here is an emerging body of evidence suggesting that an 
enzyme’s functional characteristics can also be affected by its metabolic context 
and that temporal and spatial dynamics of enzyme interactions can be important 
determinants of enzyme functionality” (Heilmann, et al. 2004). 
 
5.3.6. In study MSL-18365, the authors report two co-purified proteins of different 
molecular weight (32 and 34 kDa, respectively) isolated from E. coli transformed 
by an expression plasmid encoding a proxy of the in planta construct. 
 
5.3.6.1 The 32 kDa protein is likely to have the same amino acid sequence as native 
cDHDPS as indicated by a combination of techniques. By themselves, none 
of the analyses conducted provided a complete characterization of the entire 
protein, though some, such as peptide sequencing, could have. We see no 
reason not to provide a complete view of this protein beyond that it might be 
inconvenient or expensive for the Applicant. 
5.3.6.2 Proteins with common start sites but of different size can have different 
biological properties. For example, the gene for GP protein in Ebola virus 
produces two variant GP proteins with common amino termini. “GP is a 
membrane glycoprotein that is located at the surface of EBOV-infected cells 
and forms the spikes on virions. Expression of GP, which is encoded by two 
overlapping reading frames, requires the insertion of a non–template-coded 
adenosine residue by a mechanism of transcriptional RNA editing. Most 
(about 80%) GP mRNAs are not edited, and they direct synthesis of the 
nonstructural glycoprotein sGP, which is secreted from EBOV infected cells. 
GP and sGP are identical at their NH2-terminal ends (295 amino acids) but 
differ at the COOH termini owing to the use of different reading frames” 
(Volchkov, et al. 2001). 
5.3.6.3 In the Ebola example, RNA editing is part of the mechanism that makes for 
two polypeptides from the same sequence of DNA. Alternative splicing can 
also create these effects. More troubling, the Ebola mechanism could not be 
determined in advance from an analysis of the GP gene. Only transcriptome 
and proteomic data will detect variant species of RNA or polypeptides. 
5.3.6.4 In section 7.1 the authors report detecting additional immunoreactive proteins 
of less molecular weight than 32 kDa. They allude without evidence or 
citation to the identity of these proteins as “degradation products of the 
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cDHDPS protein” (p. 20 of 49). Moreover, in this description it is claimed 
that the identity of the smaller proteins was confirmed during “development 
work”. 
5.3.6.5 The Authority should insist that the identity of these proteins as degradation 
products be confirmed and done so formally in a set of experiments that 
include all relevant controls. 
5.3.6.6 The identity of the 34 kDa protein is never made definitively, but the authors 
suggest that it is a contamination product of the 32 kDa protein (but the basis 
for this assertion is not clear). 
5.3.6.7 We are troubled by the Applicant’s failure to detect the 34 kDa protein using 
the goat anti-cDHDPS antiserum. This point will be raised again in 
consideration of MSL-18585. 
5.3.6.8 We are also concerned that we cannot find any description of the origin of 
this antiserum in the materials provided to us.  
5.3.6.9 The Applicant must report whether the antiserum was raised against E. coli-
produced cDHDPS, C. glutamicum DHDPS, or in planta-produced cDHDPS. 
5.3.6.10 Was the antiserum affinity purified? If so, the Applicant may have lost any 
antibodies that would bind to antigens unique to in planta-produced 
cDHDPS. 
5.3.6.11 How many exposures and how frequently were goats exposed to the 
antigen(s)? What antibody classes are in the serum? Could other classes of 
antibodies mask epitopes from those classes used in the detection assay? 
5.3.6.12 The origin of the antiserum is critical information needed to evaluate the 
claim that the gene product in plants is entirely of the structure and function 
expected. 
5.3.6.13 The complete characterization of the 34 kDa protein should be possible and 
required by the Authority, because its existence makes ambiguous the 
Applicant’s claims about the nature of the active form of the enzyme and its 
physicochemical properties. 
 
5.3.7. Even equating primary structures is an imperfect gauge of biochemical 
equivalence. A proper understanding of enzyme behaviour requires isolating it 
from the relevant cellular location. 
 
5.3.7.1 As introduced above, “there is an emerging body of evidence suggesting that 
an enzyme’s functional characteristics can also be affected by its metabolic 
context and that temporal and spatial dynamics of enzyme interactions can be 
important determinants of enzyme functionality” (Heilmann, et al. 2004). The 
physical similarity between cDHDPS and E. coli-produced cDHDPS, or 
between the latter and in planta cDHDPS will not capture the potential 
effects of regiospecificity on functionality and substrate specificity that are 
unique to the environment of the plant cell in general, or the chloroplast in 
particular. 
5.3.7.2 Indeed, when an Arabidopsis 16:0∆7 desaturase protein was maintained in the 
cytoplasm of the cell rather than the chloroplast, it still produced its normal 
product but changed the diversity of products it produced (Heilmann, et al. 
2004). The same effect was achieved by targeting cytoplasmic desaturases to 
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the chloroplast. No structural analysis alone will predict the effect of context 
on an enzyme or its potential to produce unanticipated products in a novel 
context. Therefore, structural analyses equating E. coli- and in planta-
produced cDHDPS cannot substitute for the use of in planta-produced 
cDHDPS in all biochemical and feeding experiments. 
 
5.3.8. The identity of in planta-produced forms of cDHDPS is critical and the Applicant 
must demonstrate attention to all factors affecting this determination. The three 
principle techniques used by the Applicant were peptide sequencing, MALDI-TOF 
and immunoreactivity. Anomalies or deficiencies in procedure are noted below for 
all these approaches. 
 
5.3.9. Results of N-terminal sequencing. The Applicant determined the first few amino 
acids from proteins of apparent molecular weight 33 kDa. From this size class, two 
distinct N-terminal sequences were detected. This variety of peptide forms is 
considered by the Applicant to be unremarkable because it has been seen before. 
 
5.3.9.1 However, the Applicant cites evidence from three Monsanto internal reports 
rather than the peer-reviewed literature. 
5.3.9.2 The evidence in these reports is not appended to this application and so could 
not be evaluated. 
5.3.9.3 Finally, that three other transgenes produced a variety of N-terminal peptide 
types is not evidence that the variety is normal and safe. 
 
5.3.10. What would be more reassuring is an explanation of how these types arise and an 
approach to peptide purification that could detect other variants that arise from 
post-transcriptional or post-translational processing. 
 
5.3.11. We consider that the Applicant could have discovered this reported variety of 
polypeptides only by sequencing and therefore may have missed other species of 
this protein. Coupled with the unresolved identity of additional immunoreactive 
polypeptides (discussed in the following section), this suggests that the Applicant 
may not have made positive and comprehensive identifications of all novel proteins 
arising from the modifications of LY038. 
 
5.3.12. Confirmation of identity using goat anti-cDHDPS antiserum (Lot 7104510). We 
reiterate from above our concern that the Applicant has not, to our knowledge, 
disclosed the methods used to produce this antiserum. As we discussed in Part One, 
without a full 2D proteomic survey of novel proteins in LY038, we cannot begin to 
exclude the very real possibility that a variety of variant forms of cDHDPS, with 
variation introduced through alternative splicing and post-translational 
modifications, have been missed by the Applicant. Some of these forms may be 
invisible to antisera raised against protein sourced from bacteria (see our discussion 
in the next section for references). 
 
5.3.12.1 The authors report (MSL-18585, p. 21 of 46) that a “few additional 
immunoreactive bands of lower molecular weight were observed…for both 
the plant-produced and E. coli-produced cDHDPS proteins” and assert that 
“[t]hese bands were identified previously as degradation products of the 
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cDHDPS protein”, citing study MSL-18365. This conclusion is not justified 
by the findings in MSL-18365. 
5.3.12.2 As we indicated above, the Applicant provided no evidence in MSL-18365 
that the smaller proteins were indeed degradation products. In MSL-18365, 
the authors state that “a few additional immunoreactive bands of lower 
molecular weight were observed…these bands were identified during 
development work as degradation products of the cDHDPS protein” (p. 20 of 
49). The authors of MSL-18365 referred to conclusions drawn during 
development work that, to our knowledge, have not been published or 
provided for evaluation by anyone. 
5.3.12.3 MSL-18365 was a study that included no material from plants and therefore 
provides no evidence to support the conclusion that in planta-produced lower 
molecular weight bands are degradation products of full size cDHDPS. 
 
5.3.13. There remains the possibility that the Applicant failed to detect all potentially 
immunoreactive forms of protein. Glycosylation (discussed in detail in the next 
section) or its absence can create different antigenic epitopes from those present in 
otherwise identical polypeptides. For example “O-linked glycosylation has a 
profound effect on the antigenic properties of peptides. O-linked glycosylation can 
generate a neo-epitope (e.g., CII), or can have as an effect the hiding of an epitope 
(e.g., VF13N). O-linked glycosylation can mimic other epitopes (molecular 
mimicry of cytokeratins). It can change the properties of an epitope even without 
really being part of the epitope (CD43 and GPA)” (Van den Steen, et al. 1998). 
 
5.3.14. The identity of all novel proteins produced in planta directly or indirectly because 
of the modification or choice of recipient is the absolute obligation of the 
Applicant. The Authority should not relax its standards on these identifications, 
particularly as making proper identifications on these alleged degradation products 
is squarely within the bounds of biochemical techniques available to the Applicant. 
 
5.3.15. The authors attempted to detect glycoforms of in planta-produced cDHDPS. 
Glycoforms of a protein are sugar-modified variants of the same primary amino 
acid polymer. We argue that all variants, not just glycoforms, must be characterized 
because different forms can have different biochemical characteristics. MSL-18585 
has failed to convince us that all variants of cDHDPS arising from post-
translational modifications of in planta-produced cDHDPS have been detected. 
The mass spec data reassures us that the purified protein has no glycoforms, but 
again, the Applicant should identify all novel proteins produced in LY038, not just 
present the protein that is concentrated by their purification scheme. 
 
5.3.15.1 Post-translational modifications are alterations to the chemical structure of a 
polypeptide that are not controlled by the reactions in translation. They are 
therefore not specified in the DNA sequence for a gene. More than 300 
different types of chemical modifications are known, and they are distributed 
among the following: phosphorylation, glycosylation, acetylation. No 
modification is exclusive so combinations of modifications and groups of 
modifications can co-exist on the same protein (Norregaard Jensen 2004). 
5.3.15.2 Glycosylation. The three main post-translational protein modifications that 
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use carbohydrates are N- and O-linked glycosylation and glycosyl 
phosphatidyl inositol (GPI) anchors (Van den Steen, et al. 1998). Over half of 
all proteins are glycosylated (Van den Steen, et al. 1998). A single protein 
can emerge with a large variety of different glycoforms despite being 
synthesized in the same cell at the same time (Rudd and Dwek 1997). There 
may be many more forms of glycosylation than discussed above (Manzi, et 
al. 2000). Little is known about these other forms of modification, but 
procedures have been developed to isolate proteins with such modifications 
(Manzi, et al. 2000). 
5.3.15.3 Glycosylation is a significant complexity in protein analysis. It is critical that 
the Applicant fully characterize glycosylation for two reasons. First, failing to 
do so can invalidate subsequent analyses that use procedures or reagents 
dependent on knowing the full glycosylation status of the in planta-derived 
protein. Second, the biochemical characteristics of proteins with different 
types or amounts of glycosylation are factors of safety. 
5.3.15.4 Confidence in chemical purification of all glycoforms. Glycosylation can 
change the characteristics of a protein in such a way as to cause it not to be 
detected by methods that rely on the overall chemical properties of the 
protein or on antibiodies. Various glycosylation patterns can lead to different 
biochemical and antigenic properties. It would be much better if the 
Applicant had first developed a glycoprofile of LY038 (Manzi, et al. 2000), 
and worked from that to an identification of all cDHDPS variants. 
5.3.15.5 Glycosylation can significantly change the molecular weight and charge 
profiles of proteins; both of these parameters are relevant to the Applicant’s 
isolation method. 
5.3.15.6 For example, in a study comparing glycoforms of the CJD prion-forming 
protein it was found “that human brain and CSF [species of] PrPC exist [as] 
full-length and truncated species that exhibit variable degrees of 
glycosylation, giving rise to over 60 charge isomers” (Castagna, et al. 2002, 
p. 344). 
5.3.15.7 Glycoforms of the PrpC protein in humans, for example, can alter the 
apparent molecular weight by 50% (Castagna, et al. 2002). If the minimum 
molecular weight of in planta-produced cDHDPS were 33 kDa, then possible 
variants could weigh in as high as 50 kDa. 
5.3.15.8 It is not made adequately clear from the METHODS how glycosylation might 
affect the Applicant’s isolation procedure and whether all glycosylated forms 
of the protein would be fairly represented in the final stock solution. 
5.3.15.9 Purification based on activity would specifically fail to detect glycoforms 
with low or no activity in the test assay, but which still present a risk as 
allergens or novel activities. 
5.3.15.10 Therefore, the cDHDPS purification methods used by the Applicant should 
be quality assured to concentrate all glycoforms. Putative glycoforms could 
be identified in a full proteome comparison of LY038 and an unmodified 
control. Failing this, their result demonstrating an absence of glycosylation 
could be a false negative result due to exclusion of one or more minor forms 
that are glycosylated. 
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5.3.15.11 We note that in application A524 (Food derived from herbicide-tolerant 
wheat MON 71800, subsequently withdrawn by the Applicant) the Applicant 
augmented their isolation procedure with a second, immunological isolation 
and purification procedure. Although neither of these approaches is perfect, 
both should be used. 
 
5.3.16. Factors of safety. Different glycoforms can have different biochemical 
characteristics. For example, different strains of prions (e.g. the causative agent of 
Mad Cow Disease and vCJD) derive from different glycosylation patterns 
(discussed in Rudd, et al. 1999). 
 
5.3.17. We recommend that the Applicant prepare or provide a complete proteomic 
analysis of LY038 accounting for all changes. Each change should be identified as 
either a variant of cDHDPS or an unintended change in the modified plant. All 
variant forms of cDHDPS should be characterized for glycosylation or other post-
translational modifications. 
 
5.3.18. Alternative splicing can create other variants. “The diversity of gene products 
originating from a single gene is mainly due to alternative splicing of transcripts 
and co- and post-translational modification of proteins. The human genome is 
predicted to contain on the order of 30,000 open reading frames, each of which, on 
average, may produce five or six different mRNA species. Each of these mRNA 
species is in turn translated into proteins that are processed in various ways, 
generating on the order of 8–10 different modified forms of each polypeptide 
chain. Thus, the human genome may potentially produce on the order of (30 
000×6×10) 1.8 million different protein species” (Norregaard Jensen 2004). To our 
knowledge, this observation is not unique to humans and may well include maize. 
 
5.3.19. Errors are one source of alternative transcripts. Exon skipping occurs if splicesome 
components formed at the 5’ end of one exon interact with the 3’ components of a 
non-adjacent exon. Given the weak consensus around important splice sites, it is 
possible that upon occasion some sequences are mistaken as splice sites. 
 
5.3.20. Not all alternative splice products are thought to be errors. Some transcripts always 
give rise to different mRNAs. Alternative splicing may also be regulated, arising 
only in certain kinds of cells or under certain physiological conditions. Examples: 
 
5.3.20.1 A single gene in the fly Drosophila, DSCAM (Down syndrome cell adhesion 
molecule), produces some 38,000 different mRNAs from alternative splicing 
(Schmucker, et al. 2000). “The isolation of multiple cDNAs from rat and cow 
revealed that over 1000 different neurexin mRNAs could potentially be 
synthesized from three genes by virtue of alternative promoter usage and 
alternative splicing” (Graveley 2001). 
5.3.20.2 Alternative splicing may do more than just mix and match exons in different 
transcripts. The exon may be skipped or include intron sequences (exon 
extended), or the transcript may include an intron as an exon (Cartregni, et al. 
2002). 
 
5.3.21. Alternative transcripts and start codons can arise unexpectedly from transgenes 
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and, in some cases do not support enough protein product to be detected by protein-
level analysis (Burke, et al. 2000). There is new evidence suggesting that the nos 
terminator sequence used in LY038 and most commercial GMOs is a splice site 
(Rang, et al. in press) and a recombination hotspot (Kohli, et al. 1999). 
 
5.3.22. The proteomic data recommended above should be supplemented with microarray 
data to complete the description of the LY038 and parental transcriptomes. 
 
5.3.23. Description of the transcriptome would also increase the chances of detecting any 
unanticipated changes in gene expression at other loci. De novo methylation often 
occurs in GMOs, and methylation is one mechanism of gene silencing. Methylation 
changes have been directly attributed to transformation of plants with transgenes 
(Weld, et al. 2001) and later through creation of hybrids with GMOs. 
 
5.3.23.1 “Using two stable rice lines with introgression from wild rice, Zizania 
latifolia, we found marked changes in DNA methylation and transcription in 
several cellular genes and transposon (TE)-related segments had occurred 
compared with the rice parent. Changes in methylation and transcription was 
also observed in an independently produced asymmetric somatic hybrid of 
rice and Z. latifolia, which involves a different rice genotype, but also 
contains genomically integrated Zizania DNA. The changes in both 
methylation and expression in the two introgression lines were stably 
inherited through generations, and may have contributed to some of the 
phenotypic novelties, including plant statue, disease-resistance and changes 
in yield components, that are characteristic of these lines [sic]” (Liu, et al. 
2004). 
 
5.3.23.2 This is yet another justification for imposing the special condition that no 
hybrids formed with LY038 are considered approved even if the LY038 
event is approved. 
 
(6) Substantial equivalence data. 
 
6.1 Compositional 
 
6.1.1. In MSL-19172 the Applicant compares the composition of LY038 to the negative 
segregant control, LY038(-). The test and control substance were grown at five 
replicated field sites in the U.S. In addition, four different commercially available 
conventional maize lines were grown at each of the five sites, for a total of twenty 
different conventional lines replicated once. Forage and grain samples were 
collected and analyzed for nutritional components. 
 
6.1.2. The Applicant concluded from this study that “LY038 is considered to be 
compositionally equivalent to conventional maize except for the intended 
increases” in high lysine corn. 
 
6.1.3. It is not clear to us how the Applicant arrived at this conclusion. We outline the 
reasons for this lack of clarity below. 
 
6.1.4. Of the 396 comparisons made between LY038 and LY038(-), 103 were statistically 
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different (see Figure 4). This would mean that expression of cDHDPS, the effects 
of introducing I-DNA into the pre-LY038 line, subsequent processing by Cre 
recombinase, or the variability between environments in which LY038 would be 
routinely cultivated has introduced a statistically significant difference in 26% of 
the characters measured between these sibling lines. In order to gain a sense of how 
significant this difference between such closely genetically matched lines is, the 
Applicant should provide an analysis of variance of individuals within each line 
grown under matched conditions simultaneously. 
 
6.1.5. The Applicant argues that of these 103 statistically significant differences, 81 (see 
Figure 4) were still “within the 99% tolerance interval of the population of 
commercial references”.   
 
6.1.5.1 It is difficult to reconcile how differences in the composition of LY038 with 
its closest genetic match, LY038(-), can be dismissed because its composition 
is within the variance of commercial references that are genetically distant to 
LY038 [in comparison to LY038(-)] and to each other. This would argue that 
LY038 is very unlike LY038(-) because the two have become as dissimilar as 
either is to genetically distant lines of corn, and these differences could be 
due to a very different mixture of genetic and physiological factors that could 
only have arisen from the modification of LY038. 
6.1.5.2 Is the variance between unrelated lines so large that it dwarfs variances 
between related, but distinct, lines? If so, then these commercial lines are no 
better a control than LY038(-) which, as we already know, has 103 
statistically significant differences with LY038. 
6.1.5.3 Is the variance between environments more important than the variance 
between lines? If so, then the 99% tolerance interval is meaningless unless 
we know all the kinds of conditions that LY038 may be grown in and 
determine if the metabolic profile of LY038 in each of those environments is 
acceptable for human food. 
 
6.1.6. Fourteen of the 22 differences (see Figure 4) that were outside the tolerance 
intervals were intended differences in lysine and free lysine, and differences in the 
associated lysine catabolite saccharopine in grain tissue. There is 100-times more 
saccharopine by weight in LY038 than in LY038(-) and at least 50-times more than 
in the reference controls. While differences in the production of saccharopine may 
have been anticipated, they are not intended and must be the subject of further 
studies (discussed below). 
 
6.1.6.1 The Applicant finds the α-aminoadipic acid and saccharopine content of other 
common foods can be as high as or higher than levels in LY038. However 
consumption of these products is significantly less than the average 
consumption of maize. Based on United States per capita maize consumption 
(0.52 g/kg BW/day), the mean consumption of saccharopine is estimated to 
be 290 µg/kg BW/day. This is more than 15-times the mean consumption of 
saccharopine in food containing high levels of saccharopine (e.g. button 
mushroom: 19 µg/kgBW/day). Even if the per capita maize consumption in 
Australia and New Zealand were less than half that of the United States, or 
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0.2 g/kg/day, the level of saccharopine from LY038 would be an estimated 
109 µg/kg BW/day. This would be more than five times the mean 
consumption of saccharopine in food containing high levels of saccharopine. 
Therefore, contamination of the human food supply with LY038 could 
introduce consumers to saccharopine at unprecedented concentrations. 
 
6.1.7. The remaining eight statistically significant differences between LY038 and 
LY038(-) that were also outside the 99% tolerance intervals were considered 
unimportant either because their test values fell within ranges reported historically 
or within ranges reported in the scientific literature or because the difference 
between the absolute values of the test range and the tolerance interval were very 
small. The difference in the experimental conditions yielding historical and 
literature values makes it impossible to assess their relevance to LY038. So there 
remain some statistically significant differences between LY038 and LY038(-) that 
also fall outside the 99% tolerance interval that, in our view, cannot be dismissed 
simply because “the difference in the range of these values from the tolerance 
interval of commercial references was very small”. Accepting this explanation 
would be to deny the relevance of the 99% tolerance interval. Should the Applicant 
wish to deny the relevance of the 99% tolerance interval, then the 103 statistically 
significant differences between LY038 and LY038(-) must be accepted as 
indicating compositional non-equivalence. 
 
6.1.8. We could not find measurements for asparagine and glutamine levels, separate 
from combined levels of aspartate + asparagine and glutamate + glutamine, in 
LY038. This concerns us because of their importance in potentially generating 
unwanted products by the Maillard reaction during cooking or processing. The 
Authority should insist that these amino acids be measured and related to the 
tolerance intervals of standard reference lines grown under matched conditions 
simultaneously. 
 
6.1.9. Recent work has shown that “NMR combined with chemometrics and univariant 
statistics can successfully trace even small differences in metabolite levels between 
plants” (Le Gall, et al. 2003). This technique has been successfully tested using 
modified tomatoes. These findings make obsolete the observation in several recent 
review articles that metabolomics is still an uncertain science for assessing risk, 
and we recommend that this analysis be supplied to the Authority by the Applicant. 
 
6.2 Informational 
 
6.2.1. There are significant effects of RNA and DNA that are not measured through a 
description of the average content of ribo- and deoxyribo-nucleotides, nor even 
through the average content of polymers. Small RNA molecules, on the order of 
<30 nucleotides, for example, are potent gene regulators, giving rise to phenomena 
such as RNA interference (Cogoni and Macino 2000, Hannon 2002). 
 
6.2.2. Microarray descriptions should be capable of detecting novel RNA species in the 
modified plant, with the RNA source being the plant grown under a variety of 
relevant field conditions. The microarray should comprehensively represent the 
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genomes of the cultivar of maize modified and unmodified. Since LY038 may be 
found in food, variant RNAs should be screen using a microarray for the human 
genome. 
 
(7) Measures of allergenicity characteristics, acute oral toxicity, and broiler growth are either 
too poorly described to meet our minimum standards for evaluation or are inadequate to 
meet our minimum standards for confidence in safety. 
 
7.1 Allergenicity 
 
7.1.1. The value of report MSL-18676, which purports to assess the potential 
allergenicity using a simulated gastrointestinal digestion assay, rests on the 
conclusion that E. coli-produced cDHDPS is in all relevant ways identical to in 
planta-produced cDHDPS. The Authority should note that in previous sections of 
this submission we have raised serious doubts about this conclusion. Besides, the 
Applicant should be using digestibility data to demonstrate that in planta-produced 
protein is equivalent to E. coli-produced cDHDPS using protein from both sources. 
All novel proteins in LY038 should be included in this comparison (not just the 
purified cDHDPS). 
 
7.1.2. The FAO/WHO would seem to agree with us. They state that “the expressed 
protein should be assessed in its principal edible form under identical pepsin 
degradation conditions to those used to examine the expressed protein” 
(FAO/WHO 2001, p. 12). The Applicant only tested the latter, i.e. expressed 
protein isolated from E. coli. 
 
7.1.3. There is no apparent justification for not using in planta-produced cDHDPS. 
 
7.1.3.1 In planta-produced material was available because it was used in MSL-
18585. 
7.1.3.2 Using in planta-produced cDHDPS is the most straightforward and 
transparent way to conduct this study. 
7.1.3.3 The Authority may recall from the NZIGE submission on application A524 
(Food derived from herbicide-tolerant wheat MON 71800, subsequently 
withdrawn by the Applicant), comparability between the digestibility of the 
protein (CP4 EPSPS) produced either in planta or in E. coli could only be 
achieved when the Applicant used significantly different protocols. Without 
the results of a digestibility study using in planta-produced cDHDPS, the 
Authority cannot make a responsible determination of how well the E. coli-
produced cDHDPS represents in planta-produced cDHDPS. 
 
7.1.4. While it is our considered opinion that this study should not substitute for a 
properly conducted digestibility analysis using in planta-produced cDHDPS, we 
will also assess MSL-18676 on its own merits. 
 
7.1.5. Digestibility studies are essential because proteins that do not digest readily can be 
allergens, as the Applicant’s researchers indicate (e.g. Bannon, et al. 2003). 
 
7.1.6. The correlation between resistance to digestion by pepsin and a protein’s potential 
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to be an allergen is in doubt because some allergens are readily digested and some 
non-allergens are resistant to digestion (Fu, et al. 2002). Industry-independent 
observers note that “[l]ater work, however, cast some doubt on the usefulness of 
this test since few of all known food allergens demonstrate resistance to simulated 
gastric fluid (SGF-containing pepsin) or to simulated intestinal fluid (SIF) 
comprising pancreatin (a mixture of five enzymes: amylase, trypsin, lipase, 
ribonuclease, and protease). An explanation for the lack of correlation between 
SGF digestability and nonallergenicity may be that both children and adults may 
have naturally or iatrogenically increased ventricular pH for extended periods” 
(Poulsen 2004). 
 
7.1.7. The variability in human stomach pH is a key concern. It is known that infants 
have generally high stomach pH (approximately 3.0-4.0 and can be higher after 
food intake). The normal pH of an adult stomach is 2.0 but can raise to 5.0 after 
food intake (Schmidt, et al. 1995, Thomas, et al. 2004). Yet MSL-18676 reports 
analyses conducted at pH 1.2. 
 
7.1.8. An important study compared pepsin-catalysed hydrolysis of whey proteins at pHs 
ranging from 2.0 to 4.0 and found that, at the pH of the infant stomach, antigenic 
epitopes were much more likely to survive and potentially pass into circulation 
(Schmidt, et al. 1995). 
 
7.1.9. It should be noted that it will not be only adults that could be exposed to LY038 in 
their food supply. It would not be easy for parents of infants to avoid products 
derived from corn. 
 
7.1.10. The relevance of measuring digestibility at pH1.2 is never made clear by the 
Applicant, beyond alluding to the recent demonstration that a group of industry and 
industry-led laboratories has established a common protocol to optimize 
reproducibility in these assays14 (see Thomas, et al. 2004). Whereas there may be 
virtue in establishing a standard, it remains unclear why the FAO/WHO protocol is 
not the standard nor why reproducibility is a greater virtue than using a pH relevant 
to conditions in the stomach during a meal, such as pH4-5 (Schmidt, et al. 1995, 
Thomas, et al. 2004). 
 
7.1.11. The Applicant’s study also deviates from FAO/WHO recommendations on the 
pepsin to protein ratio. 
 
7.1.11.1 The Applicant used 10AU15 pepsin/µg E. coli-produced cDHDPS. Based on 
the experimentally observed activity of 3791AU per mg pepsin powder, there 
would be 2.64µg pepsin/10AU. FAO/WHO recommends 200µl of 0.32% 
(w/v) pepsin per 500µg protein (0.32% is 0.32mg/100ml, or 0.64µg in 
200µl). The FAO/WHO recommendation is 0.001µg of pepsin/1µg cDHDPS, 
approximately 2,000 times less pepsin by weight compared to the amount 
used in MSL-18676. 
                                                 
14Citation mis-identified as Bannon et al. in MSL-18676 bibliography. 
15Activity Units, or Units as defined by Applicant. 
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7.1.11.2 The weakness of the FAO/WHO protocol is that it does not control for 
variability in pepsin activities between studies. But an advantage of the 
FAO/WHO protocol is that it creates a more realistic ratio of pepsin to 
protein (Taylor 2003) in the relevant environment, the stomach (conditions 
that are not standardized for AU of pepsin). Which is the more important 
variable—pepsin activity variation between studies, or the different ratio of 
pepsin to protein in stomachs vs. in vitro assays—remains to be determined. 
In our opinion, it is the obligation of the Applicant to experimentally resolve 
this issue. 
 
7.1.12. Probably the most important control for comparability between studies would be 
the use of a common set of control proteins, as recommended by the FAO/WHO. 
“Both known non-allergenic (soybean lipoxygenase, potato acid phosphatase or 
equivalent) and allergenic (milk beta lactoglobulin, soybean trypsin inhibitor or 
equivalent) food proteins should be included as comparators to determine the 
relative degree of the expressed proteins pepsin resistance” (p. 12). We could not 
find these controls in MSL-18676. 
 
7.1.13. In the absence of such controls, we must agree with Taylor who says that even “a 
10x ratio of pepsin to protein…is arguably ridiculous because in vivo protein would 
always exceed pepsin” (Taylor 2003). Certainly then, 2,000x pepsin is an excess 
that should be more carefully justified. 
 
7.1.14. The Applicant should report digestibility measurements after processing. Nearly all 
native proteins are digestible using pepsin. Whether food proteins are digestible 
depends not just on their inherent digestibility, but also on the degree to which they 
have been modified during food processing (Meade, et al. in press). The extent to 
which cDHDPS expressed in maize and mDHDPS will be modified during food 
processing is unknown. Known differences in sequence (Mirwaldt, et al. 1995) and 
presumed differences in tertiary and quaternary structure (see above) are likely to 
affect the degree to which the protein is modified. This could influence proteolysis 
in the gut. It is entirely possible that cDHDPS would be less digestible post-
processing, increasing its potential to elicit an immune response. 
 
7.1.15. The digestion studies were submitted in part to reassure FSANZ and the public that 
the modified corn has low potential as a novel source of allergens. It is our view 
that these digestion studies were fundamentally flawed with regard to conclusions 
of allergenicity. Our argument is that: 
 
7.1.15.1 the techniques used to assess the digestibility of cDHDPS event were 
inconsistent with international minimum standards; 
7.1.15.2 these standards were set by FAO/WHO, and FSANZ assessments are meant 
to be compliant with FAO/WHO principles; 
7.1.15.3 no studies were performed on in planta-produced protein or processed foods 
derived from LY038, making unintended effects creating potential allergens 
undetectable (Pusztai, et al. 2003). 
 
7.1.16. We recommend that the Authority require the Applicant, at a minimum, to supply 
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data on the digestibility of the cDHDPS protein using a protocol compliant with the 
FAO/WHO standard and the recommendations of Pusztai et al. (Pusztai, et al. 
2003). 
 
7.1.17. The literature in the past several years has indicated that extrapolation from in vitro 
studies is no substitute of tests using animals (Pusztai, et al. 2003). For example, 
the Cry1Ab protein from genetically engineered corn survived digestion in the 
stomach of pigs and was detected by ELISA, immunochromatography and 
immunoblot in the intestine, despite it being shown to be highly digestible through 
the type of in vitro studies reported for E. coli-produced cDHDPS (Chowdhury, et 
al. 2003). Similarly, large fragments of the cry1Ab gene found in corn survived 
digestion and were detected in fecal material (Chowdhury, et al. 2003). 
 
7.1.18. Interestingly, DNA and protein from the natural source (Bacillus thuringiensis 
subsp. kurstaki) was not detected in control pigs, indicating that the concentration 
of this material, or its structure, when present in feed corn differs from the material 
introduced into food through natural contamination by soil microorganisms. The 
differences are worthy of investigation. Many other studies also based on in vivo 
data of protein or DNA stability have made similar claims. It is our view that in 
vivo data from reliable studies will always be more trustworthy than extrapolations 
from in vitro data. 
 
7.1.19. Furthermore, the Applicant should address possible effects of novel foods on the 
intestinal flora. In vitro studies cannot do this. Few if any in vivo studies have been 
designed to do this (aside from looking at microbial recombinants arising from 
transgenic DNA surviving digestion (Netherwood, et al. 2004)). Data are 
accumulating that soil flora can be affected by some forms of transgenic crops, 
such as Bt rice (Wu, et al. 2004). If soil flora are affected, then intestinal flora 
could be affected. The intestinal flora are critical to good health. Disease states 
arise from subtle shifts in population structure, not just the introduction of new 
pathogenic species (Berg 1995, Berg 1996). 
 
7.1.20. In MSL-18744, the Applicant compared the primary amino acid structure of 
cDHDPS to known allergens using bioinformatics tools to identify any similarities 
between cDHDPS and confirmed allergens. Reassuringly, no significant matches 
were detected. 
 
7.1.21. Bioinformatics tools have never been validated as comprehensively predictive of 
potential allergens. So such approaches are useful when they return a match rather 
than when they return no matches. 
 
7.1.22. These types of tools are highly dependent on the quality of data provided to them. 
Search algorithms will not extrapolate the sequence space, for example, to potential 
polypeptide products arising from alternative splicing. 
 
7.1.23. We have identified some peptide sequences that could arise from inclusion of parts 
of the rACT1 intron by alternative splicing for analysis. We analysed these 
peptides using AllermatchTM (Fiers, et al. 2004). While the results are not striking, 
this casual analysis retrieved a significant match to the known allergen Cla h 3 
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from Cladosporium herbarum. Since all alternative transcripts and peptides not 
properly processed for import into the chloroplast cannot be predicted in advance, 
the Applicant should produce algorithms that explore the sequence space of 
possible alternative transcripts and compare them to known allergens. 
 
7.1.24. The Applicant should also provide evidence that novel proteins produced by 
LY038 pose no new risks due to a propensity to form aggregates as discussed in 
Part One. 
 
7.1.25. A new resource for predicting the aggregation potential of proteins has recently 
become available (Fernandez-Escamilla, et al. 2004). This bioinformatics approach 
is based on a statistical mechanics algorithm called TANGO, a free web resource. 
It has been successfully trialled on 179 polypeptides from 21 different proteins and 
it successfully predicted the aggregation potential of up to 92% of the polypeptides. 
 
7.1.26. The algorithm cannot be used to make quantitative comparisons of highly divergent 
polypeptides. Moreover, it is in theory less accurate with polypeptides over 40 
residues. Nevertheless, it has demonstrated a qualitative efficacy in making 
predictions on longer polypeptides and provides guidance as to whether a protein 
has regions prone to seeding aggregation. 
 
7.1.27. In our analysis of cDHDPS and mDHDPS, we found a different sequence 
landscape for aggregation potential (see Figure 5). These results suggest that high 
quantities of cDHDPS in the human diet may increase exposure to new forms of 
protein with properties different from mDHDPS. The safety of these species in 
food is unknown. 
 
7.2 Acute oral toxicity and broiler feeding trials. 
 
7.2.1. In MSL-18735 (acute oral toxicity), the Applicant fed 40 mice in two groups of 10 
animals per sex, with either the test protein, cDHDPS, or a control protein, BSA. 
The target doses were 1000 mg/kg body weight. The test protein was cDHDPS 
isolated from E. coli. Each mouse received a single dose of the protein by gavage 
followed by ad libitum feeding on commercial feed for the 14 day trial. No 
significant weight changes were detected over the trial. 
 
7.2.2. The first difficulty with this study is that the protein should have been sourced from 
LY038 rather than E. coli. This point has been made repeatedly by the scientific 
community (Pusztai, et al. 2003). The Applicant needs to address this and supply 
results of properly conducted studies before it is possible to make an informed 
decision on the application.  
 
7.2.2.1 Further, when this is done, toxicity tests on the whole crop are needed. 
“[C]ases where the composition of the whole crop has been changed 
significantly compared with the traditional counterpart16, or where there is a 
need to further investigate potential unintended side effects of the genetic 
                                                 
16Note that LY038 differs significantly in many ways from its traditional counterpart and, importantly, from 
its closest nontransgenic relative, as discussed in section 6. 
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modification, warrant additional toxicity testing” (Kok and Kuiper 2003, p. 
440). As unintended side effects have been found in recent tests of other 
genetically engineered plants (Pusztai, et al. 2003), and 103 statistically 
significant differences were reported in MSL 19172, there is reason for 
additional toxicity testing here. 
 
7.2.3. In any supplemental study, it is essential to weigh and observe the organs of the 
sacrificed animals. We recommend that the Authority disregard the Applicant’s 
claims on acute oral toxicity until MSL-18375 is supplemented with the 
information we believe is essential. “The biological, immunological, hormonal 
properties and allergenicity of” LY038 maize must be determined using the maize 
product and not surrogate sources such as E. coli (Pusztai, et al. 2003). 
 
7.2.4. In MSL-18883 the Applicant compared the growth performance of broilers when 
fed diets containing LY038, LY038 x MON810, negative segregant control 
(LY038(-)), or four lots of commercial maize. No differences were found between 
broilers fed diets containing LY038 or LY038 x MON810 maize and broilers fed 
lysine-supplemented diets containing either control (LY038(-)) or commercial 
maize. 
 
7.2.5. Adding lysine to the corn-diet of the broilers enhanced the adjusted weight gain 
considerably, as expected, but the growth of broilers given transgenic corn (GM) 
that produced higher amounts of lysine (LY038 and LY038 x MON810) was less 
dramatic during the first 21 days (see Figure 6). Broilers fed GM corn had 
significantly lower adjusted gain in the first 21 days relative to feed than groups fed 
conventional corn supplemented with similar amounts of lysine (p=0.008; t-test). 
This result suggests that there may be an unexpected and unexplained negative 
factor acting on broilers fed GM lysine-producing corn that prevented them from 
reaching the same growth rates as broilers fed conventional corn. 
 
7.2.6. While no unintended effects were found in the broilers fed with LY038 maize, we 
recommend that the Authority seek blood tests and data on organ weights and 
visual observations. 
 
7.2.7. We also were troubled by the apparent contamination of LY038 seed stock by 
MON810, a different transgenic line, reported in this study. Individual PCR 
analysis found that up to 20.5% of LY038 seed carried the MON810 event, or that 
up to 20.5% of the seed was MON810. This was also confirmed using an 
immunological detection method. 
 
7.2.7.1 The Applicant goes on to say that “the presence of the MON810 trait was 
considered as an ‘inert ingredient’ that would not impact the objectives and 
interpretation of this study” (MSL-18883, p. 23 of 165). In our view, the 
presence of substantial quantities of MON810 invalidates claims about 
LY038 because it has substantially diluted any concentration-dependent 
effects of the high lysine line. 
7.2.7.2 We do not at this stage trust that MSL-18883 delivers reliable assessments of 
LY038 effects on broilers. Coupled with the problems we discuss 
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immediately below, we recommend that the Authority dismiss study MSL-
18883 for purposes of assessing safety. 
 
7.2.8. There is another anomaly with the design of A549. Why were none of the 
commercial corn lines used in MSL-18883 included in MSL-19172 (compositional 
analysis)? Surely the most complete analysis would have used a set of lines 
common to both studies. 
 
7.2.9. Strikingly, LY038 had higher levels of 16 of the 20 measured amino acids among 
the four commercial lines used as references in MSL-18883. The only amino acid 
(ignoring lysine) in which LY038 was not the highest or equal highest producer 
was proline (Table 1, Appendix 1 of MSL-18883). While we do not know how 
significant any individual measure is between LY038 and one of the commercial 
lines, it would seem an enormous coincidence if LY038 was the highest of the five 
lines in 16 amino acids by chance. 
 
7.2.10. This raises questions about the design of MSL-18883, which appears flawed by 
chance or design to produce the greatest growth effect on the broilers. 
 
7.2.11. And it raises other important questions. How would including these four 
commercial lines, each with amino acid levels clearly on the lower end of the 
spectrum, have influenced the 99% tolerance intervals calculated in MSL-19172? 
Our brief look suggests that the commercial lines in MSL-18883 frequently fall 
outside the 99% tolerance intervals in MSL-19172 (Table 1) and therefore would 
likely lower the interval. In many cases, LY038 was closer to the upper end of the 
tolerance interval. Including the four commercial varieties used in MSL-18883 in 
MSL-19172 might have revealed many more statistically significant differences in 
composition between LY038 and conventional corn. 
 
7.2.12. We recommend that a compositional analysis that includes the four commercial 
varieties used in MSL-18883 be requested by the Authority. 
 
Table 1. Amino acid analysis for LY038 and commercial corn. 
Component Tolerance Interval MSL-191721 Average MSL-188832,3 LY0384 
Glutamic Acid 16.76-22.36 14.95 23.20 
Leucine 10.15-15.62 9.28 15.10 
Methionine 1.54-2.41 1.63 2.55 
Phenylalanine 4.49-5.68 3.70 5.74 
Threonine 2.73-3.62 2.76 3.87 
1Table 14. MSL-19172 
2of four commercial references in Table 1, Appendix 1 MSL-18883 
3numbers in bold are outside 99% tolerance interval measured in MSL-19172 
4as reported in MSL-18883 
 
7.3 Additional data needed. 
 
7.3.1. Giroux et al. (1999) measured cholesterol concentration in serum and lipoprotein, 
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and liver phospholipids, in their feeding study on rabbits (Giroux, et al. 1999), 
finding significant differences in rabbits fed diets enriched in lysine or lysine and 
methionine. We could find no similar measurement in MSL-18735, or in the 
summary of the LY038 feeding study (Monsanto Australia Limited 2004, p. 103)17, 
and recommend that this type of data be submitted to the Authority. 
 
7.3.2. Renwick (2004) lists the minimum essential characteristics of complete amino acid 
toxicity safety tests, which we reproduce in Table 2 (Renwick 2004). “Data from 
studies on humans may be of particular importance in the risk assessment of amino 
acids to confirm the absence of reversible adverse effects detected in animal studies 
(tolerability studies) or to define the potential human variability in biodisposition” 
(Renwick 2004, p. 1618S). Chronic testing is essential for establishing the 
allowable daily dose, however Renwick suggests that for amino acids “short-term 
and subchronic repeat-dose studies such as 90-d or 6-mo studies are of greater 
relevance…It is now widely recognized that studies of 6- and 9-mo duration in 
rodents and nonrodents are sufficient for identification of possible hazards except 
cancer and for dose-response assessment of noncancerous effects [emphasis 
added]” (Renwick 2004, p. 1619S). 
 
7.3.3. The Authority should specifically consider requesting that the Applicant use the 
promising pig intestinal model for assessing amino acid toxicity (Baracos 2004). 
These models show promise for assessing the “maximal gut capacity to deal with 
amino acid insults under different physiological conditions” (Baracos 2004, p. 
1658S). “The downregulation of intestinal protein degradation by amino acids 
contributes to controlling amino acid entry into free pools from proteolysis in the 
function of the dietary supply. Our models can be used to identify maximal 
response and the amino acids most potent in eliciting this change…This approach 
has application in studies to define the upward limits of the adaptive regulation of 
intestinal amino acid catabolism in response to high amino acid doses” (Baracos 
2004, p. 1658S). 
 
7.3.4. Cancer and other potential harms require lifetime feeding studies. Not all potential 
carcinogens or co-carcinogens may be related to the amino acids per se, but due to 
other changes in the GMO. That material must be used in such studies (Pryme and 
Lembcke 2003, Pusztai, et al. 2003). 
 
7.3.5. We recommend that the Applicant provide a valid subchronic toxicity study of a 
minimum of 6 months duration. 
 
7.3.6. We recommend that the Authority require toxicity testing commensurate with the 
recommendations of Table 2. 
 
                                                 
17Primary data was not released to us. 
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Table 2. Characteristics of amino acid toxicity safety tests. 
Toxicity Needed testing 
Acute Usually single-dose study 
Short-term Repeated doses for 14-28 days in actively growing animals 
(starting weight 80 grams for rats) 
Subchronic Repeated doses for 6-9 months (informs parameters for 
subsequent chronic toxicity study) 
Chronic Repeated doses for 2 years in rodents; 3 years rats 
Reproductive Dosing before, during and after gestation 
Intestinal Pig model 
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Part Three: Assessment of Impact Analysis 
 
(8) Jurisdictional issues 
 
8.1 Lack of clarity regarding the impacts relevant to the Analysis. 
 
8.1.1. FSANZ jurisdiction covers the food supply, yet the focus of the Impact Analysis is 
on the implications of the use of LY038 as animal feed.  
 
8.1.2. This raises problems for the evaluation of the application. Because FSANZ’s 
jurisdiction is food safety, it seems that responses to the IAR in general, and the 
Impact Analysis in particular, that point out difficulties with regard to the 
importation of LY038 as feed are likely to be set aside during the FSANZ process. 
This creates a Catch-22 for assessing the Impact Analysis, and, thus, the proposed 
amendment to the Code. 
 
8.1.3. We urge FSANZ to re-examine whether the Impact Analysis should in fact include 
costs and benefits of importing or not importing LY038 as feed. If it decides in 
favour of such inclusion, we urge it to take into account the additional costs and 
benefits we identify. 
 
8.2 The Applicant’s assurance that LY038 is intended only as animal feed may have 
coloured the composition of the application.  
 
8.2.1. Our understanding of the Food Code is that any genetically modified organism that 
is permitted into the human food supply is considered safe at any concentration or 
frequency at which the unmodified organism may be consumed—not safe only at 
or below certain concentrations or frequencies of exposure. 
 
8.2.1.1 Even if contamination of the human food supply with LY038 were 
infrequent, or particular consignments had low concentrations, the 
concentration of the material may not be uniform in any food or consignment, 
resulting in some individuals experiencing higher than average exposures to 
the product. These individuals ought to be as safe in consuming the product 
as those who consume none of it. 
 
8.2.2. Our reading of A549 leaves us with the impression that the Applicant has assumed 
that a lower standard may be required for approval in this case, perhaps because 
there is no stated intent to have it become part of the human food supply. This is 
suggested by: 
 
8.2.2.1 The level of detail and strength of replication are much less for A549 than in 
some other applications, such as A524, and significantly decrease the 
potential for the Applicant to discover an unanticipated hazard. For example: 
8.2.2.2 MSL18365 adds to the volume of work submitted in support of the 
application, but fails to include the obvious controls, mDHDPS and in planta-
produced cDHDPS, for its conclusions. 
8.2.2.3 The Applicant purified in planta cDHDPS using only one type of isolation 
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scheme whereas in other applications this approach was augmented using 
immunological purifications techniques. 
8.2.2.4 In contrast to A524, A549 lacks a digestibility comparison between E. coli-
produced and in planta-produced protein. 
8.2.2.5 In contrast to A524, A549 lacks data on human immune responses. 
8.2.2.6 In the Applicant’s discussion of a feeding study that was not a part of the 
materials released by FSANZ for independent review (Monsanto Australia 
Limited 2004, p. 103), they say “This level of exposure far exceeds the 
estimated human dietary exposure resulting from the inadvertent introduction 
of Lysine maize LY038 into the human food chain [emphasis added]”. Thus, 
in this case their safety margin relies upon a frequency and concentration of 
contamination that is low rather than on an assurance of safety per se. 
8.2.2.7 In the Acute Oral Toxicity Study of A549 (MSL-18735) the animals were 
dosed with only one concentration of the test protein (cDHDPS), compared to 
the same study in A524 where three different doses were tested. 
 
8.3 The proposed amendment would permit not only accidental or ‘minimal’ 
contamination; it would legalise any quantity of LY038 corn in food. Therefore, 
LY038 must be found safe regardless of the current intention on the part of the 
Applicant or any other producer of LY038 or public agency to segregate the product 
from corn intended for the human food supply. We urge the Authority to disregard 
the declared intention of the Applicant to segregate LY038 from the human 
food supply, and to ensure that the declared intention influence neither the 
standards of rigour expected of the application nor the analysis of the impacts of 
amending the Code. 
 
(9) Impact Analysis 
 
9.1 The inclusion of costs and benefits to users of LY038 as animal feed 
 
9.1.1. While FSANZ is not responsible for the evaluation of GM animal feed imports, its 
Impact Analysis considers several costs and benefits derived from using LY038 as 
animal feed. Since the material provided does not explain why failure to amend the 
Food Code will prevent animal growers from accessing LY038 feed, we can only 
speculate. 
 
9.1.2. Is it feared that LY038 will contaminate human food after it is imported into 
Australia and New Zealand as feed? This would imply that the Australian and New 
Zealand food-industry practices of segregating imported feed grains from food 
intended for human consumption are inadequate. If the response to inadequate 
practices in another sector is to amend the Code, then we fail to solve the primary 
problem. The first priority of the Code is to protect the safety of the food supply. 
Amending the Code should not, in our view, become so commonplace that it is 
used as an easy way to avoid solving other kinds of problems. If such segregation 
practices are indeed inadequate, this in itself should be a major concern of FSANZ. 
 
9.1.3. If it is not feared that LY038 will contaminate the human food supply after its 
importation as feed, then it remains unclear how this regulatory decision could 
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directly impact upon the availability of animal feed in Australia and New Zealand. 
 
9.1.4. Is it feared that if Australia and New Zealand do not agree to permit LY038 in their 
food supplies, the Applicant will no longer grow LY038 at all, and therefore it will 
not be available to anyone? If this is the argument, then it should be stated 
explicitly and subjected to FSANZ and public scrutiny. It seems highly unlikely 
that the ability of LY038 to access the Australia/New Zealand food market would 
decide its global fate. If the implication here is that the costs of segregating LY038 
from human food are prohibitive to the producers of LY038, then it must be 
recognised that should the Code be amended, such costs would fall on those 
seeking GM-free food (and feed). 
 
9.1.5. If, on the other hand, seeking approval in Australia/New Zealand is part of the 
Applicant’s business strategy to exert pressure on other food authorities directly or 
through the WTO, then this, too, should be explicitly stated and subjected to public 
scrutiny. This strategy has costs for growers, consumers, citizens, and governments 
in Australia and New Zealand. 
 
9.1.6. In sum, we see no evidence or argument to suggest that the impacts of this 
regulatory decision fall upon animal growers. The contamination and commingling 
under discussion relate to corn seed and food products imported from LY038-
growing countries. It seems that the declared intention to use LY038 only as feed 
has resulted in the misidentification of the Affected Parties (by focusing on animal 
growers, their suppliers and customers). We believe that as a result FSANZ is not 
in fact in a position to claim, as it does in its Statement of Reasons for accepting 
the Application, that “there is no reason to believe that costs arising from such a 
variation to include food derived from corn line LY038 would outweigh the direct 
and indirect benefits to the community, Government or industry that would arise 
from the variation.” The relevant direct and indirect costs and benefits of the 
variation have not yet been scoped. 
 
9.1.7. Finally, in our view it would be impermissible to give weight to impacts related to 
the animal-feed market when the Applicant was not required to provide 
information related to the safety and management of LY038 as an animal feed and 
FSANZ has no jurisdiction to determine its safety or suitability in this form. The 
benefits and costs of the use of LY038 as animal feed are therefore included 
without the appropriate investigation or evaluation. We are concerned that 
FSANZ will base its decision in part on alleged benefits of LY038 that are 
apparently irrelevant to the Application and that it is not equipped to 
evaluate. 
 
9.1.8. Since these feed-related statements have been included, however, it is necessary to 
appraise them, and we do so below. 
 
9.2 FSANZ defines Regulatory Option 1 as “not amending the Code to approve the sale 
and use of food derived from corn line LY038.” Here we comment on the potential 
costs and benefits of this Option. 
 
9.3 “Industry: Cost to animal growers as a possible reduction in the variety of animal 
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feed products available. Cost to animal growers to source either segregated or non-
GM feed.”  
 
9.3.1. As noted above, the material does not clarify why failure to amend the Code will 
prevent animal growers from accessing LY038 feed. 
 
9.3.2. It seems that these alleged costs would be incurred only as a result of overseas’ 
suppliers inability to implement the kinds of quality-control measures that are 
essential to the traceability and product-chain monitoring required by some of our 
major markets. FSANZ appears to be asking Australians and New Zealanders to 
bear the risks that these suppliers’ lack of quality control creates. 
 
9.3.3. The inadvertent and occasional lapse in segregation leading to rejected 
consignments for human use would not amount to significant cost, certainly not 
above what should be routinely borne by those who benefit from the sale of 
LY038. Should this not be the case, then we question whether the segregation 
procedures are as effective as claimed. If they are not, then the characterization of 
the amounts of LY038 expected in the human food supply as “likely to be low” is 
misleading. 
 
9.3.4. Assuming, as the Impact Analysis does, that this regulatory decision would impact 
upon the composition of the animal-feed supply, the Impact Analysis fails to note 
the benefits of Option 1 for animal growers wishing to avoid GM animal feed. 
 
9.3.4.1 Rather than a speculative “possible reduction”, this benefit is immediate and 
measurable, in that it would obviate these growers’ otherwise necessary 
additional costs and other obstacles to maintaining a GM-free feeding regime. 
9.3.4.2 The size of these benefits may be considerable. The New Zealand Ministry of 
Agriculture and Forestry has acknowledged that “views on the feeding of 
genetically modified grain to poultry are one potentially significant influence 
on the direction of the poultry meat industry” (Ministry of Agriculture and 
Forestry 2003), projecting that, for the pig meat industry, if New Zealand 
grain crops remain free of GM, “the industry may be able to establish a 
national pork brand of ‘raised on GM free grain’ and gain a comparative 
advantage over other pork exporting countries” (Ministry of Agriculture and 
Forestry 2003b). The anti-GM-feed consumer sentiment that would prompt 
such a move is gaining momentum. A consortium of supermarkets in Britain 
removed GM crop-fed meat from their house brands in 1999 after concerns 
were raised by consumers (Woolf 1999), with this trend spreading to 
supermarkets across Europe. This suggests significant benefits to those who 
can keep GM feed out of their animal production process. Measures that 
reduce obstacles for these animal growers should be appropriately 
recognized. 
 
9.4 “Industry: Cost in terms of restricting innovation in food/crop production for both 
growers and other sectors of the food industry.” 
 
9.4.1. This alleged cost is speculative because no evidence has been presented that Option 
1 would result in something as sweeping as “restricting innovation in food/crop 
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production”. One could as readily argue that Option 1 will encourage innovation—
for example, ways of accomplishing the same nutritional goals through genomics-
assisted conventional crop breeding or other alternative ways of delivering the 
alleged benefits of LY038, ways that could prove highly marketable in themselves. 
 
9.4.1.1 As noted in Part One, there are high lysine mutants in maize that are not the 
product of genetic engineering and could potentially be an alternative to 
LY038. 
 
9.4.2. The “cost in terms of restricting innovation in food/crop production” must be offset 
by the benefits of not imposing new costs and constraints on those in the food 
industry developing and marketing GM-free products. 
 
9.5 Option 1: WTO issues 
 
9.5.1. The Impact Analysis lists as costs of Option 1: “Government: Potential impact if 
considered inconsistent with WTO obligations but impact would be in terms of 
trade policy rather than in government revenue.” “Industry: Potential longer-term 
impact - any successful WTO challenge has the potential to impact adversely on 
food industry.” 
 
9.5.2. Because it is no one’s intent to introduce LY038 into the human food supply, 
Option 1 would presumably require only infrequent rejection of a consignment due 
to LY038 contamination. Occasional rejection on these grounds cannot legitimately 
be considered a non-tariff trade barrier if exercised only when the product was not 
of the composition expected. Thus there is little reason to expect Option 1 to be 
considered inconsistent with WTO obligations.   
 
9.5.3. Moreover, WTO agreements must make allowances for importing countries should 
producers routinely fail in their obligations to demonstrate adequate care in the 
production, distribution and processing of human food. No international agreement 
should be used to justify poor quality-control procedures. 
 
9.5.4. If, however, the argument here is that any refusal to allow a product (or a GM 
product, or a GM product from the United States) into the food supply should be 
considered a cost because someone might consider it inconsistent with WTO 
obligations, this should be made explicit and subjected to public scrutiny. Such an 
approach is inconsistent with FSANZ’s three primary objectives under Section 10 
of the Act: to protect the public's health and safety; to provide adequate information 
relating to food to enable consumers to make informed choices; and to prevent 
misleading or deceptive conduct. We note that a significant proportion (two out of 
five) of the impacts considered in the analysis of Option 1 relate to putative WTO 
concerns. 
 
9.6 In light of the considerations outlined above, we believe that the Impact Analysis 
overstates the costs and understates the benefits of Option 1. 
 
9.7 FSANZ defines Regulatory Option 2 as “amend[ing] the Code to permit the sale and 
use of food derived from corn line LY038, with or without listing special conditions 
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in the Table to clause 2 of Standard 1.5.2.” Here we comment on the potential costs 
and benefits of this Option. 
 
9.8 “Consumers: Possible benefit of lower prices for poultry and swine food products, to 
the extent that savings from animal production efficiencies are passed on.” 
 
9.8.1. Again, it is unclear why allowing LY038 in food (not feed) would impact upon the 
price of poultry and pork. 
 
9.8.2. However, as this is being posited, we would like to draw attention to the 
conditional language in this statement. As it seems no price details have been 
settled on by the Applicant, it is impossible to determine the economic advantage 
or disadvantage LY038 entails for the food industry and consumers, compared with 
conventional high lysine corn or lysine supplements. This proposed benefit should 
be underpinned by an economic analysis that compares the projected cost of LY038 
with the cost of conventionally adding lysine. 
 
9.8.3. Similarly, no evidence has been presented that the potential costs of using LY038 
incurred by animal growers (such as those related to segregation and monitoring, 
intellectual property, or overall nutritional value of the feed) will not offset its 
potential economic advantages. 
 
9.8.4. Further, no evidence has been presented that any cost savings that might result 
would in fact be passed on to consumers. This would depend on a range of 
(unassessed) factors, including, for example, the market positions of producers, 
processors, distributors, and retailers. 
 
9.9 “Consumers: The amount of LY038 corn entering the food supply is likely to be low 
so the cost to consumers wishing to avoid GM food by a potential restriction of 
choice or products, or increased prices for non-GM food is likely to be low.” 
 
9.9.1. This statement rests on the Applicant’s declared current intention to import LY038 
only as animal feed. However, the proposed amendment to the Code will approve 
LY038 for human consumption. We contend that any decision that is premised on a 
mere intention, which will not be secured by the regulation itself, is not appropriate 
or acceptable regulatory practice. 
 
9.9.2. The proposed amendment is itself likely to weaken the declared intention. Once 
LY038 is legal in the food supply, there would be little incentive to minimize 
contamination. The Applicant would be compelled to maintain such stringency 
only if the amendment were declined. The current intentions and segregation 
measures emphasized by the Applicant are therefore inconsequential and should 
not figure in the Impact Analysis. 
 
9.9.3. In their discussion of the Broiler Growth Trial (MSL-18883), the Applicant 
revealed that their LY038 stocks were contaminated with MON810 (see section 7). 
This case demonstrates that even the seed producer has difficulty maintaining 
separate stocks and suggests that the measures used by the Applicant are less 
reliable than claimed, or that the cost of monitoring to achieve reliable segregation 
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is prohibitively high. Given that the Applicant has not prevented the substantial 
contamination of its seed stock, FSANZ should scrutinize the claim that LY038 
will only infrequently and at low quantities contaminate human food supplies. 
 
9.9.3.1 Should FSANZ recommend amending the Code for the event in LY038, then 
it is critical that threshold criteria be established in Column 2 of the Table to 
Clause 2 of Standard 1.5.2 indicating below which levels and frequency of 
contamination, and range of contaminated products, LY038 events would be 
seen as inadvertently contaminating the human food supply and what the 
consequences would be for contamination above these thresholds. 
 
9.9.4. The increasing incidence of coeliac disease among Australian and New Zealand 
consumers suggests a potentially serious impact of the introduction of LY038 into 
the food supply. Coeliacs are allergic to specific wheat, barley, rye and oat 
proteins; corn is one of the few remaining staple grains they are able to eat. Should 
coeliacs develop an allergic response to LY038, even its adventitious presence in 
the food supply will have serious consequences for them. Incidence of the disease 
is estimated at 1:300 (Kennedy and Feighery 2000). Studies in Australia and New 
Zealand have confirmed equal or greater rates in local populations (e.g. Hovell, et 
al. 2001, Cook 2004). A thirty-year study of diagnoses in the Canterbury region 
found rising rates of the disease among both adults and children over that period. 
Adult prevalence is noted as 1:83 in the Christchurch area (Cook 2004). The 
special dietary requirements of this large section of the population reaffirm the 
importance of carefully screening the introduction of new ingredients to the food 
supply. The range of products identified by the Applicant as vulnerable to 
contamination further argues against the estimation of a “low” impact on 
consumers wishing to avoid GM food. The possibility that the proposed 
amendment may result in the elimination of more foods from coeliacs’ already 
strict eating plan should be considered a significant cost. 
 
9.9.5. The statement implies that those wishing not to consume LY038 will bear the cost 
of avoiding LY038. There are three difficulties with this suggestion. 
 
9.9.5.1 First, only if the Code were amended to permit LY038 would it become the 
burden of the citizen to pay to avoid LY038. The status quo places the burden 
on those who benefit from the sale of the product. Thus, opting for Option 2 
has a guaranteed impact on the citizen regardless of whether there is financial 
cost; Option 2 creates a new imbalance of power between consumer and 
producer. 
9.9.5.2 Second, the cost of demonstrating that a product is LY038-free will be just as 
high whether LY038 is a rare or a frequent contaminant of other corn-derived 
products. The testing is not simpler nor is it necessarily less rigorous or 
frequent. It will have to be conducted continually without certain knowledge 
of when or where the contamination will occur. Evidence should be provided 
for the assertion that the cost of avoiding LY038 will be low. Our 
internationally peer-reviewed work on monitoring does not lead us to this 
conclusion (Heinemann, et al. 2004).  
9.9.5.3 Third, since the Applicant’s case is that LY038 will only rarely contaminate 
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corn intended for human consumption, the cost of that assurance ought to be 
borne by the Applicant and/or others who benefit financially from the 
production of LY038, as is the case under Option 1. Thus, we think FSANZ 
has inappropriately underestimated the impact on the consumer of opting for 
Option 2. 
 
9.10 “Government: Benefit that if LY038 were to inadvertently enter the human food 
supply, this application will ensure any corn imports from the United States comply 
with the Code. This would ensure that there is no potential for trade disruption on 
regulatory grounds.” 
 
9.10.1. We find this statement troubling and inconsistent with the Authority's three primary 
objectives: to protect the public's health and safety; to provide adequate 
information relating to food to enable consumers to make informed choices; and to 
prevent misleading or deceptive conduct.  
 
9.10.1.1 To regard as a benefit the facilitation (through removal of disincentives) of 
adventitious contamination of the food supply with (GM) animal feed cannot 
be regarded as protective of the public's health and safety, either in itself or 
through the precedent it sets.  
9.10.1.2 “Ensur[ing] that there is no potential for trade disruption” requires measures 
that will simultaneously ensure that the public will not be provided with the 
information they need in order to make informed choices regarding LY038-
contaminated food, as they will not be made aware of the presence of the 
contaminant (and at the same time, as we noted above, the proposed change 
to the Code makes such contamination more likely). 
9.10.1.3 Increasing the likelihood that the public remains unaware of instances of 
adventitious contamination of the food supply (i.e., by removing the 
regulatory and trade dimensions that might draw attention to it) could 
facilitate misleading and deceptive conduct by the food industry, particularly 
by those who export to us. 
 
9.10.2. If we were to take this alleged benefit to its logical conclusion, the Code would be 
amended to permit any and all food imports and contaminants thereof, or at least 
those from the United States, in order to minimize the overall “potential for trade 
disruption on regulatory grounds”. Such a position is in obvious and direct conflict 
with the Authority's primary objectives. 
 
9.11 “Government: This decision may impact on monitoring resources as food derived 
from corn line LY038 will be required to be labelled as GM and may be required to 
be labelled as having altered characteristics.” “Industry: Possible cost to food 
industry as food derived from corn line LY038 will be required to be labelled as 
genetically modified and may be required to be labelled regarding its increased 
lysine levels.” 
 
9.11.1. In contrast to many of the benefits of Option 2 suggested by the Impact Analysis, 
monitoring and labelling costs are immediate and certain, rather than speculative, 
impacts of the proposed amendment. The implications should therefore be more 
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carefully detailed, showing the extent to which the introduction of LY038 might 
impact already stressed resources with unique monitoring requirements to be 
applied to the full range of products the Applicant has identified as being at risk of 
contamination. The list is extensive, and it is reasonable to expect a significant 
impact on monitoring resources. Similarly, the costs of labelling will certainly 
impact upon the food industry.  
 
9.11.2. While the frequency and amount of contamination are irrelevant to the standards of 
the scientific safety evaluation, they are not irrelevant to the Impact Analysis. 
When the cost to producers of GM-free products increases because they must 
monitor their sources for GM material, that cost is permanent and considerable 
irrespective of the frequency of contamination. GM-free producers cannot opt to 
monitor only when they know their product has been contaminated. New Zealand 
has learned numerous times in the past four years how difficult it is to detect GM 
material and to attempt to monitor it correctly (Heinemann, et al. 2004). That 
lesson is well documented in the international, peer-reviewed scientific literature. 
 
9.11.3. A review of the economic impact of LY038 should also consider the costs involved 
in the post-launch monitoring recommended in the event of an amendment (see 
3.6). 
 
9.11.4. All of this argues that the costs, both to industry and to government, are more than 
just possibilities and that they are likely to be considerable. 
 
9.12 “Industry: Possible benefit to animal growers in terms of a wider range of feed 
products. Benefit to importers and distributors of overseas feed products as the 
product range is extended.” 
 
9.12.1. Again, nowhere in the material provided is it explained why amendment of the 
Code is necessary in order to import LY038 animal feed. 
 
9.12.2. Increasing the feed products on the market is not necessarily a benefit for animal 
growers. We note that in a recent review commissioned by the New Zealand Food 
Safety Authority, the Poultry Industry Association of New Zealand “expressed 
strong concerns that there were insufficient controls on the importation of…raw 
materials that are ingredients for animal feed” (External Review Team 2004). 
 
9.12.3. This “possible benefit” must again be offset by the certain cost to growers who 
wish to avoid GM feed, and to distributors and exporters who wish to maintain 
GM-free product lines, in that the approval of this feed will increase the obstacles 
they face to maintain this standard.  
 
9.13 FSANZ should also consider that New Zealand will ratify the Cartagena Protocol on 
Biosafety. This makes New Zealand’s international obligations different from 
Australia’s and means that there are additional significant impacts for New Zealand. 
For example, should some LY038 seed contaminate New Zealand feed corn crops, 
then New Zealand will be subject to special requirements for reporting on its own 
corn exports. 
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Conclusion 
 
The submitter is a recognized research centre in biosafety with expertise in molecular 
biology and genetics in general and genetic engineering in particular, social and political 
science, biochemistry and protein science.  
 
Having examined the application, our conclusion is that significant additional information 
should be provided by the Applicant before a decision is made on whether to amend the 
Australia New Zealand Food Code to allow food derived from LY038. There have been 
significant advances in biosafety and risk assessment science that are not consistently 
reflected in the standard of reporting in A549. The studies submitted in support of A549 do 
not consistently meet what we see as the standard of the science. 
 
Having examined the Impact Analysis, our conclusion is that it is necessary to clarify which 
costs and benefits to which Affected Parties are appropriately included in an application to 
amend the Food Code. Further, we have identified a number of questionable inclusions, 
omissions, and assumptions, the result of which is an Impact Analysis that overstates the 
benefits and understates the costs of amending the Code. We have also raised bona fide 
issues of safety that have not been addressed by the Authority or the Applicant, which also 
increase the cost of amending the Code.  
 
On the basis of the evidence and analysis provided thus far, amending the Food Code to 
permit the use of LY038 in food cannot be justified. 
 
 
 
Respectfully submitted on behalf of all authors,  
  
Assoc. Prof. Jack Heinemann 
Director  
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Figure 1 
Examples of integration events that may lead to false negative results using long probes. 
Compared to controls (usually fully intact, full length plasmid DNA identical to the probe) 
and full length insertions, partial fragments appear as ghostly or light bands since the 
combination of the stringency in washes and the efficiency of binding at these sites would 
act to reduce the amount of probe retained. Below some threshold number of base pairs 
between probe and target DNA, the Southern would not detect the insert. Nevertheless, 
each insert is relevant to risk identification. The minimum standard in reporting should be: 
1. supply controls showing size detection limits (i.e. determine the threshold for returning a 
positive result) at the same stringency used to conclude the absence of an insert; 2. 
sequence all ghost bands. 
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Figure 2 
Reproduction of Figure 19 from Application A549 (Monsanto Australia Limited 2004, p. 
33). Green horizontal lines (top 2) are bands unique to Lysine maize LY038 (Xho I and 
Xba I). Cyan horizontal lines (bottom 3) are bands seen in both Lysine maize LY038 (Xho 
I and Xba I) and LY038(-) (Xho I and Xba I). Red circles are bands that may be in common 
in both LY038(-) (Spe I) and Lysine maize LY038 (Spe I), and in LY038(-) (Spe I) and 
Lysine maize LY038 (Spe I). 
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Figure 3 
Reproduction of Figure 21 from Application A549 (Monsanto Australia Limited 2004, p. 
46). Red circle is band that may indicate hybridization between plasmid backbone probes 
and LY038 genome. 
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Statistical evaluation: 
LY038 vs LY038(-) 
Test range compared with 
the 99% tolerance interval 
from commercial maize 
6 Sets of comparisons were analyzed 
  5 Comparisons with data from each    
environment (field trial) 
   1 Comparison with data from a  
combination of all field trials 
369 Comparisons 
7 Test values fell within 
ranges reported historically 
or in the scientific literature  
1 “Small” difference in the 
test value from the 99% 
tolerance interval 
14 Differences in lysine, free 
lysine and saccharopine 
81 Within 99% 
tolerance interval 
22 Outside 99% 
tolerance interval 
103 Statistically 
different 
293 Not statistically 
different 
66 Components were 
statistically assessed (56 
grain, 10 forage) 
Figure 4 
Statistical assessment of the compositional data (MSL-19172).
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Figure 5 
TANGO graphical predictions of aggregation potential and regions of greatest aggregation 
potential for cDHDPS and mDHDPS. 
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Figure 6 
Mean and 95% confidence intervals of Adjusted Gain:Feed for broilers fed different 
treatments from day 0 – 21. —Lysine (all non-GM maize types without lysine added; 
n=60), + Lysine (all non-GM maize types with lysine added; n=60) and GM (LY038 and 
LY038 x MON810; n=20). Data is extracted from the original report and shows a 
summarized excerpt of Graph G1 in Appendix III.  
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